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Abstract 
Development of EGFR-targeted Contrast Agents for In Vivo Applications 
by 
Dawn Lynn Nida 
Optical techniques targeting biomarkers of cancer have the potential to aid in the 
early detection of this disease. Molecular and biochemical changes in neoplastic tissue 
could be interrogated, potentially providing an objective assessment and identification of 
suspect tissue. A method of interrogating such changes involves the development of 
optical based probes that provide a molecular-specific source of signal. 
This dissertation aims to develop an effective optical strategy to target the 
epidermal growth factor for in vivo detection. The optical probe design consists of an 
optically active component (quantum dot, fluorescent dye) and a molecular specific probe 
(antibody, peptide). The optically active components investigated were cadmium 
telluride quantum dots (QDs) and Alexa Fluor 647 dye. Epidermal growth factor 
receptor (EGFR) was chosen as a molecular target because it is over-expressed in a large 
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number of epithelial cancers. Both peptides and antibody to EGFr were investigated as 
molecular specific probes. 
The work presented in this dissertation provides a systematic approach for 
developing optically active probes targeting EGFR. The ability to synthesize, passivate 
and functionalize red-emitting QDs was investigated. It was demonstrated that in order 
for QDs to be properly passivated for biological imaging applications, a crosslinked 
amphiphilic-based polymer should be used. Such polymers afforded the best surface 
protection of all the coating strategies tested. Unfortunately, such systems are generally 
very large (>35nm) and therefore might be hindered in in vivo delivery. 
Due to the large size of QD-based optical probes, further research in this 
dissertation utilized the commercially available dye, Alexa Fluor 647. Alexa 647 was 
tethered individually to three different proteins: anti-EGFR antibody; mouse epidermal 
growth factor peptide (mEGF); and human epidermal growth factor peptide (hEGF). The 
specificity of each Alexa 647-protein conjugate was verified in vitro. Each protein-dye 
conjugate was further investigated to determine the specificity and efficiency of 
intravenous delivery to EGFR positive and EGFR negative tumors. These investigations 
revealed the importance of both the mean fluorescent signal (normalized for dye:protein 
ratio) as well as distinctive, recognizable patterns of contrast agents for in vivo 
applications. Such criteria yield a contrast agent with the best case scenario for being 
detected and recognized. 
The use of a systematic approach to design and test contrast agents for in vivo 
applications was demonstrated through this work. This work stressed a comprehensive 
investigation including in vitro, ex vivo and in vivo testing. Additionally, it was shown 
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that care must be taken in designing in vitro experiments to interpret in vivo results as the 
two do not necessarily correlate. This dissertation lays the groundwork for the 
development of contrast agents targeting specific molecular markers of cancer. 
I would like to dedicate my dissertation and all of its trials and turbulations to my family: 
together we make the fearsome foursome plus two: Mom, Dad, Kathy, John and Dane. I 
love you all so very much! 
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CHAPTER 1: INTRODUCTION 
1.1 Motivation 
The epidermal growth factor receptor (EGFR) is a 170-kD transmembrane 
receptor tyrosine kinase that, in binding six ligands, stimulates the proliferation of a wide 
variety of animal cell types [1, 2]. EGFR is expressed ubiquitously in cells and is over-
expressed in human malignancies including breast cancer, glioma, and lung cancer 
making it a promising biomarker of neoplasia [3]. Activation of the epidermal growth 
factor receptor has been shown to contribute to the proliferation and spread of many 
different types of solid tumors. The over-expression of EGFR has been correlated with 
many processes related to cancer, including uncontrolled cell proliferation, autocrine 
stimulation of tumor growth by tumors producing their own growth factors, and 
prevention of cellular apoptosis. Additionally, EGFR levels increase as the severity of 
the lesion progresses from early dysplasia to carcinoma in-situ [4]. 
Epidermal growth factor receptor expression can potentially act as an early 
indicator of disease or the progression of disease possibly aiding in the detection of 
epithelial cancers in vivo. In this dissertation, I will investigate strategies for targeting the 
epidermal growth factor receptor. These strategies will be based on an optical probe that 
ideally emits in the red wavelength range allowing optimal light penetration and a 
biomolecule that targets EGFR. 
1.1 Specific Aims 
The primary goal of my research was to determine an effective optical, non-
invasive strategy to target the epidermal growth factor receptor for in vivo detection. For 
this to be accomplished, the following specific aims were set: 
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(1) Synthesize and functionalize red-emitting Quantum dots for optical imaging 
applications. The overall goal of this aim was to create a water-soluble particle resistant 
to degradation and flocculation that would easily be functionalized with a protein 
enabling it to be conjugated to a biomolecule targeting EGFR. The choice of cadmium 
telluride (CdTe) quantum dots was based upon their advantageous spectral characteristics 
and the ability to create monodisperse particles emitting in the red wavelength range. As 
synthesized quantum dots were organic soluble, non-passivated and non-targeted. In 
order to have a useful quantum dot, we had to ensure that surface bonds were satisfied 
(and therefore passivated) and that we could tether a protein onto the surface for specific 
targeting. This was accomplished by encapsulating a QD within a phospholipid micelle 
that could be further tethered to an antibody or protein through functional moieties at the 
distal end of the micelle chain. 
(2) In vitro validation of three different proteins targeting EGFR. The three 
targeting proteins investigated were mouse epidermal growth factor peptide (mEGF), 
human epidermal growth factor peptide (hEGF), and a monoclonal anti-EGFR 
humanized antibody each conjugated to the red-emitting dye, AlexaFluor 647. 
Validation of each protein-dye was performed in vitro using an EGFR positive cancerous 
cell line (1483 epithelial oral cancer) and an EGFR negative cancerous cell line 435S 
(metastatic breast). Targeting capabilities of each protein-dye conjugate were adjusted 
for the amount of dye per protein. Additionally, competition assays between protein-dye 
conjugates and each respective free protein were performed as additional tests of 
conjugate specificity. 
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(3) To investigate the performance of three different proteins targeting EGFR in 
vivo. In order to understand the transition from in vitro validation to in vivo applications 
of the three protein-dye conjugates, excised tissues from both 1483 and 435S mouse 
xenografts were used. This served to aid in understanding the complexities of labeling 
tissue versus labeling cells in a monolayer, and to validate that each conjugate worked on 
tissue before pursuing in vivo studies. Excised EGFR positive or EGFR negative tumors 
from a mouse xenograft model were topically labeled with each of the contrast agents to 
verify that the contrast agents worked with tissue samples. Finally, contrast agents were 
intravenously injected into the tail vein of immune compromised mice to test the delivery 
to either EGFR positive or EGFR negative tumors. The labeling patterns and amount of 
protein reaching the EGFR was determined and compared between antibody and 
peptides. 
1.2 Dissertation Overview 
The second chapter includes portions of a book chapter which I wrote that 
appeared in Advances in Cancer Research, and provides the motivation and background 
for this dissertation, including an overview of optically active targeted contrast agents for 
molecular imaging, cancer biomarkers, and delivery issues [4]. The third chapter 
includes portions of a paper that I published in Nanotechnology describing the micelle-
encapsulation process for passivating and functionalizing quantum dots. This chapter 
compares micelle-encapsulation to other amphiphilic polymer based passivation 
techniques through spectroscopy and imaging [5]. The fourth chapter investigates the 
role that the targeting protein choice plays in the labeling process by comparing two EGF 
peptides to an anti-EGFR monoclonal antibody in vitro, ex vivo and in vivo labeling of 
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oral cancerous epithelial cells. This chapter will form the basis of a future publication. 
The fifth chapter provides summary, conclusions and future directions for the 
dissertation. 
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CHAPTER 2: BACKGROUND1 
2.1 Introduction 
Cancer is a major public health problem. Worldwide, more than 6 million people 
die from cancer each year and more than 10 million new cases are detected. In the last 
decade, the enormous progress made in discerning the molecular events that accompany 
carcinogenesis has led to development of new cancer therapies directly targeted against 
the molecular changes of neoplasia. In pre-clinical and early clinical trials, molecular-
targeted therapeutics (alone and in combination) have shown impressive response rates 
and less toxicity than conventional cytotoxic therapies, which lack specificity for tumor 
cells. For example, drugs such as Erlotinib and Erbitux have increased responsiveness to 
chemotherapy and have shown responses in patients who progress on conventional 
therapy. However, in order to achieve the promise of molecular-targeted cancer 
therapeutics, a new set of tools is required to dynamically and quantitatively image and 
monitor the heterogeneous molecular profiles of tumors in vivo. This new set of tools 
can: (1) enable rational selection of a regimen of targeted therapies, given a quantitative 
image of the molecular profile of a patient's tumor, (2) provide a much more sensitive 
and rapid way to monitor the efficacy of targeted therapeutics across an entire tumor, 
enabling changes to be made quickly before a tumor has advanced to a clinically 
significant degree, (3) allow design of more appropriate clinical trials of new molecular 
agents based on alteration in molecular profiles of risk rather than maximal tolerated 
dose, and (4) provide a dynamic approach to guide conventional tumor ablation, based on 
a molecular profile of risk. 
1
 Portions of this chapter have been published previously in Sokolov, K., Nida, D., et al, 2007. Optical 
strategies to target EGFR in vivo. Advanced Cancer Research. 96, 299-344. 
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The traditional classification of cancer and its precursors is based on a phenotypic 
profile of risk, including macroscopic parameters such as tumor size, extent of invasion, 
and presence of metastases and microscopic parameters such as nuclear to cytoplasmic 
ratio, differentiation, and depth of epithelial involvement. Increasingly, molecular 
parameters of risk such as the status of the epidermal growth factor receptor (EGFR), 
estrogen/progesterone receptor, her2-neu, and c-kit, are being incorporated into clinical 
therapeutic paradigms. Currently, molecular markers can only be visualized in vitro using 
complex immunohistochemical staining protocols. In this chapter we will discuss 
emerging tools to image in vivo a molecular profile of risk based hallmarks of cancer, for 
selecting and monitoring therapy. Imaging the molecular features of cancer requires 
molecular-specific contrast agents which can safely be used in vivo as well as cost-
effective imaging systems to rapidly and non-invasively image the uptake, distribution 
and binding of these agents (Figure 1). Here, we present the combination of optically 
active, targeted nanoparticles for molecular imaging with advances in minimally invasive 
optical imaging systems, which provide tools to dynamically image both a molecular and 
phenotypic profile of risk and to monitor changes in this profile during therapy. Images 
obtained in real time through low-magnification optical microscopes can rapidly 
characterize tumor size and distribution, margin location and molecular heterogeneity 
across a large field of view, based on a molecular profile of risk. Then fiber optic 
endoscopes can be used to quantitatively image areas of potential risk in 3D with sub-
cellular resolution, in real time. The combination of 2D surface imaging and 3D high 
resolution imaging affords the ability to profile a tumor and provide precise molecular 
information with histologic-quality spatial resolution. Further, optical imaging systems 
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are inexpensive, robust and portable because of advances in computing, fiber optics and 
semiconductor technology. Thus, optical imaging systems are ideally suited for 
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Figure 2-1: Development of molecular-specific contrast agents for in vivo optical imaging 
of carcinogenesis. 
2.2 Role of Molecular Specific Optical Imaging of Carcinogenesis 
Rapid and non-invasive imaging of molecular features of cancer can provide 
unprecedented ability to study the molecular processes associated with carcinogenesis in 
vivo in humans. In particular, they can enable direct imaging of the biology of invasion 
and monitoring of host response serially over time. Below, we give examples of the 
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impact that molecular optical imaging can play in advancing molecular therapeutics into 
future clinical practice. 
2.2.1 Monitoring effectiveness of therapy 
When choosing therapy, it is important to quickly determine whether or not the 
patient is responding, to avoid progression of a non-responsive tumor. There is no 
reliable method to quickly determine the response of an individual's tumor to non-
surgical therapy. Determination of tumor response is routinely assessed 8 weeks 
(chemotherapy) or 12 weeks (radiation) after initiation of therapy by physical 
examination and radiographic scans. These methods are grossly inadequate, relying 
predominately on lesion size. Even positron emission (PET) scans have limited 
applicability in this situation. While an invasive biopsy can be performed during 
treatment, it only removes a small portion (millimeters) of the area of interest and may 
not accurately reflect overall treatment effectiveness. Furthermore, biopsy can be very 
painful due to mucositis and inflammation associated with therapy, and may lead to 
problems with wound healing. It is even more difficult to assess response of tumors to 
new, molecularly targeted therapy. For example, with anti-angiogenesis therapy, there is 
typically no major change in the gross size of tumors, despite effective blockage of tumor 
vascular neo-angiogenesis. 
Thus, advancements that improve the ability to quickly and non-invasively assess 
the response of a tumor to therapy have important benefits. Optical molecular imaging 
can provide an important new tool to accurately assess therapeutic response, bridging the 
gap between clinical exam and histologic indicators of response. Because optical 
molecular imaging can assess cell morphology, tissue architecture and cancer-related 
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biomarkers non-invasively, it provides a tool to assess response to therapy across an 
entire tumor. Thus it could enable clinicians to avoid unnecessary delay in identifying 
most effective therapy before a cancer has progressed to a stage where it is difficult or 
impossible to treat successfully. 
2.2.2 Rational selection of targeted therapeutics. 
The development of cancer is a multi-step process of genetic, epigenetic and 
metabolic changes resulting from exposure to carcinogens. For example, in the 
progression of oral carcinogenesis, an accumulating series of molecular alterations leads 
to EGFR activation, telomerase activation, up-regulation of cyclooxygenase-2 (COX-2), 
and overexpression of cyclin Dl [7-9]. Elucidation of signaling pathways involved in 
initiation and progression of malignancy has facilitated development of novel, targeted 
approaches to cancer treatment. Signaling pathways targeted by these agents include 
EGFR, vascular endothelial growth factor (VEGF), Ras, COX-2, and p53 [6], [7]. 
Understanding this progression has provided a wealth of targeted therapeutics, including 
COX-2 inhibitors (e.g. celecoxib, sulindac), tyrosine kinase inhibitors (e.g. Iressa), and 
vectors that cause lysis of cells with deficient p53 activity (e.g. Ad-p53). These agents 
represent a fundamental new approach to cancer therapy. Current cancer therapeutics 
rely on cytotoxic drugs that lack specificity for tumor cells; targeted therapeutics may 
provide greater efficacy with reduced side effects [8]. The success of targeted 
therapeutics for chronic myelogenous leukemia (CML) and gastrointestinal (GI) stromal 
tumors illustrate the unique potential of these approaches. More recent work has shown 
that combination therapies, combining targeted agents can have substantially greater 
response [9]. Many clinical trials are currently underway with agents targeting EGFR 
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and other tyrosine kinases (ZD1839-Iressa, C225-Cetuximab), Ras signaling via 
inhibition of farnesyltransferase (SCH6636), p53 gene pathways via gene transduction 
with RPR/INGN 201, and COX-2 signaling with celecoxib. However, little is known 
about how to rationally select the combination of agents for a patient and how to 
rationally design dosing schedules and monitoring strategies for future clinical trials. 
Technological advancements in optical molecular imaging can provide the ability 
to dynamically and quantitatively image the molecular profile of a tumor. This can open 
the possibility for rational selection of a regimen of targeted therapeutics, based on a 
molecular profile of risk and can provide a tool to monitor whether the targeted therapy is 
having the desired effect, enabling clinicians to avoid unnecessary delay in identifying 
the most effective therapy before a cancer has progressed to a stage where it is difficult or 
impossible to successfully treat. 
2.3 Cancer Biomarkers and Therapeutic Targets. 
Cancer results from accumulation of a series of key mutations in expanding 
clones of cells. It has been shown that these molecular events play a major role in cancer 
progression and can be valuable biomarkers for cancer diagnosis, grading and prognosis 
[10], [11]. It has been suggested that there are six acquired capabilities shared by most 
human cancers which collectively dictate malignant growth (Figure 2) [12]. In this 
chapter, we consider biomarkers associated with four of these: (1) self-sufficiency in 
growth signals (EGFR), (2) evasion of programmed cell death (anionic phospholipids), 
(3) tissue invasion and metastasis: Matrix metalloproteinases (MMPs) and (4) sustained 
angiogenesis: VEGF and its receptors (Figure 2). 
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Figure 2-2: Strategy to develop contrast agents to monitor hallmarks of cancer (Califano 
et al., 1996). Targets for contrast agents are shown in boxes outlined with dark black 
lines. Reprinted from Cell, 100, Hanahan, D., Weinberg, R.A., The Hallmarks of Cancer, 
p.57-70, 2000, with permission from Elsevier. 
2.3.1 EGFR 
Epidermal growth factor receptor (EGFR) overexpression occurs in 80-100% of 
precancerous and cancerous lesions of the oral cavity [13]. EGFR is also frequently 
overexpressed in non-small-cell lung carcinoma (NSCLC) [14], and is a target of novel 
therapeutics. There are seven known EGFR ligands, including EGF and transforming 
growth factor-alpha. Ligand binding leads to receptor dimerization and 
autophosphorylation of the receptor, which in turn activates signal transduction pathways 











2.3.2 VEGF and Its Receptors 
VEGF is a key angiogenic factor that stimulates blood vessel growth in normal 
and neoplastic tissues [15]. VEGF is expressed at high levels in malignant tissues in 
many organ sites. There are two high affinity receptors for VEGF - Rl and R2. 
VEGFR2 is thought to be the major initiator of angiogenesis in tumors. VEGFR1 and R2 
are both overexpressed in tumor cells and tumor endothelium, due both to increases in 
ligand concentration and hypoxia [16]. 
2.3.3 MMPs 
At late stages of tumor progression tumor cells invade adjacent tissue and travel 
to distant sites to form metastases. Metastases cause 90% of human cancer death [17]. 
MMPs enable invasion and metastasis and are implicated in other activities important for 
tumor growth, such as angiogenesis and growth signaling [12]. For example, it has been 
demonstrated in many studies that MMPs (MMP 1, 2, 3, 9, 10, 11, 13, MT1-MMP) are 
all expressed in oral cancer and have roles in tumor progression [18] and references 
therein]. MMP-2 and -9 are specific for collagen IV - these are the enzymes that allow 
for invasion through the basement membrane into blood vessels/lymphatics. MMP 
staining has been shown to progressively increase as the grade of the lesion or stage of 
the tumor increased. Sienel et al. showed that homogeneous expression of MMP-9 and 
MMP-2 can serve as significant indicators of poor patient survival in lung carcinomas, as 
well [19], [22]. MMP-9 was overexpressed by a factor of 2, while MMP-2 activity was 
increased by a factor of 17 in 36 lung cancer patients [23]. 
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2.4 Optical Technologies 
Molecular imaging requires two components: a molecular-specific source of 
signal (typically provided through a contrast agent) and an imaging system to detect this 
signal. In recent years, high resolution micro-PET, MRI and ultrasound have shown 
promise for molecular imaging in animal studies [20]. However, these systems are 
expensive and do not provide sufficient resolution to image sub-cellular detail in real 
time. An alternative is optical imaging. Optical imaging can be carried out non-
invasively in real time, yielding unprecedented spatial resolution (less than 1 micron 
lateral resolution). Optical imaging systems are inexpensive, robust and portable. 
Confocal microendoscopes which image near infra-red (NIR) reflected light have been 
used to image sub-cellular features in epithelial tissue at video rate to depths exceeding 
400 microns [21-37]. Optical coherence tomography (OCT) has been used to profile NIR 
reflectance, assessing tissue architecture to a depth of 2 mm, yielding information about 
the transition from in situ carcinoma to microinvasive carcinoma [38-43]. Optical 
imaging systems that detect tissue autofluorescence can give important molecular 
information, mapping the intracellular concentrations of NADH and FAD for example 
[44]. We developed two types of optical systems to image tissue non-invasively: (1) 
widefield microscopy, to image large fields of view with limited spatial resolution and (2) 
confocal microscopy, to image tissue noninvasively with subcellular spatial resolution. 
Over the last 15 years, we have intensively tested these systems to aid in the early 
detection of cervical and oral neoplasia. Later in this chapter, we demonstrate the 
integration of optical imaging devices with molecular specific contrast agents for 
monitoring of carcinogenesis. Here, we describe in detail real time optical imaging 
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technologies that allow imaging of morphologic and molecular features of neoplasia at 
two length scales. In the first, low resolution, widefield microscopes, capable of imaging 
areas with a large field of view (5-15 cm) are used to identify areas suspicious for 
neoplasia. In the second approach, high resolution microscopes, operating near the 
diffraction resolution limit, are used to image the morphologic and molecular 
characteristics of neoplastic lesions. 
2.4.1 Widefield Microscopy 
In widefield microscopy, the tissue surface is illuminated with light; light 
remitted from the surface is collected through an objective lens and directed to a detector 
to form a 2D widefield image (Figure 3). We developed simple, inexpensive systems to 
image tissue at video rate in vivo, providing information to guide placement of higher 
resolution imaging systems. In one approach, a simple colposcope (a low power 
microscope used to view the cervix) was modified to enable collection of quantitative 
images of tissue autofluorescence - the resulting device is a multi-spectral, digital 
colposcope (MDC). In constructing the MDC, we used an inexpensive (<$500), 
commercially available, video-rate, color CCD camera to capture autofluorescence 
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Figure 2-3: In vivo widefield microscopy. 
Figure 4 illustrates typical results to image autofluorescence and reflectance of the 
cervix. In colposcopy, a health care provider visually examines pattern of white light 
reflected from the cervix before and after application of acetic acid. We extended the 
ability of the colposcope to measure tissue autofluorescence, which has the potential to 
increase both specificity and sensitivity of the procedure and to guide where higher 
resolution images should be obtained [47], [46]. We explored the use of non-specific 
contrast agents such as acetic acid with the multi-spectral digital colposcope to indicate 





Figure 2-4: Multispectral digital 
microscope (top) and in vivo images of 
cervical tissue obtained with white light 
(middle) and 340nm excitation (bottom). 
Published with permission from Optical 
systems for in vivo molecular imaging of 
cancer, Technology in Cancer Research 
and Treatment, 2, 491-504, 2003, TCRT. 
We also applied widefield microscopy to demonstrate the feasibility of detecting 
tumor margins in real time in the oral cavity. To evaluate the concept of multispectral 
imaging of oral tissue, we investigated the autofluorescence of ex vivo oral cancer lesions 
at several wavelength combinations. Fluorescence of oral tissue specimens was observed 
through a widefield multispectral imaging system. Figure 5 shows typical results. The 
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system consisted of a Xenon light source, and a CCD camera. The tissue was excited at 
340, 380, 400, and 440 nm, and tissue autofluorescence was collected at 510, and 530 
nm. The specimen photographs were handed to an experienced head and neck surgeon, 
blinded to the histopathological diagnosis of the biopsies. Suspected neoplastic areas 
were encircled on photos, and compared to histologic results. Best results were achieved at 400 
nm excitation and 510 nm detection [47] and indicate that oral cavity autofluorescence 
can easily enhance a clinician's visual assessment of normal and neoplastic mucosa in the 
oral cavity. 
Figure 2-5: Images of resected oral cancer obtained with 
white light illumination (top) and 440 nm excitation, 530 
nm emission (bottom). Yellow lines represent surgeon's 
assessment of the margins of abnormal tissue. Circles are 
biopsy sites: red XA cancer, white lA dysplasia, blue lA 
normal. Published with permission from Vision 
enhancement system for detection of oral cavity neoplasia 
based on autofluorescence, Head &Neck, 26, 205-215, 
2004,Wiley. 
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These systems can be also used to image fluorescence in intact small animal 
models of neoplasia. Figure 6 shows white light and fluorescence images of 
subcutaneous tumors from MDA-MB-435 human breast cancer cells in a nude mouse 
model. Tumors formed with red fluorescence protein (RFP) expressing cells show easily 
detectable autofluorescence as early as 2 weeks following injection of the cancer cells, 
while RFP negative control tumors do not show detectable fluorescence. Micrometastases 
in the excised lung (Figure 7) can easily be detected via the RFP fluorescence. 
Figure 2-6: Multispectral images of nude mice with subcutaneous 
tumors (MDA-MB-435 cells). The top row shows white light and 
fluorescent images of tumors formed with the parental cell line, 2 
weeks following injection. The middle row shows white light and 
fluorescent images of tumors formed with RFP-expressing cells 2 
weeks after injection, while the bottom row shows images 2 months 
after injection. 
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Figure 2-7: Micrometastases in the excised lung. Left image (white light) and right image 
(red fluorescence). 
2.4.2 High Resolution Microscopy 
In order to image the morphologic and molecular changes of neoplasia with 
cellular and subcellular detail, higher resolution microscopes are required. In vivo 
confocal microscopes can provide detailed images of tissue architecture and cellular 
morphology in living tissue in near real time. In epithelial tissue, 1 micron resolution has 
been achieved with a 200-400 micron field of view and penetration depth up to 500 
microns [21-27, 35, 36, 48, 49]. A non-fiber optic version of a real-time reflectance 
based confocal microscope showed promise to detect changes associated with cervical 
precancer [35], [50]. Figure 8 shows image pairs of normal (left) and abnormal (right) 
biopsies from several patients and the corresponding histology. In each pair, the 
difference in nuclear density and area is evident between the normal and abnormal 
biopsy. Architectural similarities are also evident between confocal and histologic 
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images. The nuclear to cytoplasmic (N/C) ratio extracted from confocal images gave best 
discrimination between high grade lesions and non-high grade lesions. 
' V . 
Figure 2-8: Reflectance confocal images from the normal (left two columns) and 
abnormal (right two columns) biopsy pairs. Increased nuclear density can be seen in the 
confocal images of the abnormal samples (C, G, and K). The confocal images were taken 
50 mm below the surface. The histologic images were classified as normal (B, F, and J), 
ON II/III (D and H) and cancer (L). Scale bars in the confocal images are 50 mm and 
100 mm in the histology images. Reprinted from Academic Radiology, Vol. 9, Collier, et 
al., Near real time confocal microscopy of amelanotic tissue: detection of dysplasia in ex 
vivo cervical tissue. 
2.4.3 Fiberoptic 
Fiber optic confocal microscopes are needed to obtain images clinically [51]. 
These instruments are designed to be inserted through a speculum, catheter, large-bore 
needle, or biopsy channel of an endoscope. An example of a fiber optic reflectance 
confocal microscope with a miniature, plastic injection molded objective lens is shown in 
Figure 9 [52];[53, 54]. This system has a lateral resolution of approximately 2 microns, 
21 
an axial resolution of approximately 5 microns and can obtain images throughout the 
entire epithelial thickness in cervical tissue. 
Later in this chapter, we discuss the combination of these optical imaging 
technologies with optical contrast agents specific for cancer biomarkers. 
Figure 2-9: Miniature injection-molded 
3.3X/1.0 NA microscope objective for 
reflectance confocal microscopy. Published with 
permission from In vivo fiber optic confocal 
reflectance microscope with an injection-
molded plastic miniature objective lens, Applied 
Optics, 44, 1792-97, 2005. 
2.5 Optically Active Contrast Agents 
Luminescent organic dyes and fluorescent proteins have been traditional optical 
contrast agents and their applications in biology and medicine are described in a number 
of excellent reviews and books [55] [56] [57] [58] [59]. Recently, a new paradigm has 
emerged in development of optically active compounds which is based on nanoparticles 
with unique size-dependant optical properties [60] [61] [62] [63]. The nanoparticle 
platform offers a number of advantages over the traditional fluorescent dyes including 
greatly improved photo-stability, bright signal and simple tunability of optical properties 
[61]. Nanoparticles also provide high surface area which can be easily modified using a 
22 
variety of delivery, targeting and therapeutic moieties that enables the use of 
nanoparticles as a common platform for multiple applications [62] 
In this chapter we outline research activities in development of two emerging 
types of optically active contrast agents: those based on metal nanoparticles which give a 
strong source of reflected light, and those based on quantum dots, which are a strong 
source of luminescence. We also discuss how the unique nanoscale sensitivity of 
quantum dots and gold nanoparticles can be used to design smart contrast agents, which 
are dark in the absence of a target ligand but become brightly luminescent upon exposure 
to the ligand to select and monitor targeted therapies. These smart contrast agents rely on 
the strong ability of gold to quench the luminescence of quantum dots when in close 
proximity. 
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Figure 2-10: Contrast agent strategy. Published 
with permission from Optical Systems for in 
vivo molecular imaging of cancer, Technology 
in Cancer Research and Treatment, 2, 491-
504, 2003, TCRT. 
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Our strategies in the development of the optically active contrast agents are 
outlined in Figure 10. The agents consist of three parts: (1) a probe molecule which 
provides molecular specific recognition of cancer biomarkers conjugated to (2) a 
nanoscale optically interrogatable label in (3) a permeation enhancing delivery 
formulation. We use 3 types of molecular probes: monoclonal antibodies against cancer 
specific biomarkers, peptides selectively cleaved by cancer related enzymes and aptamers 
which undergo conformational change upon selective binding to cancer-related growth 
factors. Together, this cocktail of contrast agents can constitute a powerful approach to 
image the hallmarks of cancer at the molecular level and to monitor the effects of 
targeted therapies on multiple crucial signaling pathways, alone and in combination. 
2.5.1 Metal Nanoparticles 
2.5.1.1 Optical properties 
Gold nanoparticles have been extensively used as stains in electron microscopy of 
[64, 65]. As result, the fundamental principle of interactions between gold particles and 
biomolecules, especially proteins, have been thoroughly studied. However, colloidal 
gold nanoparticles exhibit beautiful and intense colors in the visible and NIR spectral 
regions. These colors are the result of excitation of surface plasmon resonances and are 
extremely sensitive to the sizes, shapes, and aggregation state of the particles, to the 
dielectric properties of the surrounding medium and to adsorption of ions on the particle 
surface [66]. 
The tremendous potential of using metal nanoparticles as optically interrogatable 
biological labels has recently been recognized, leading to development of a variety of 
novel applications in bioanalytical chemistry with unprecedented sensitivity [67-73]. The 
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ability to resonantly scatter light at frequencies coinciding with the particles' surface 
plasmon resonances is still to be explored for in vivo biological applications. Recently, it 
has been demonstrated that this property can be used in the development of contrast 
agents for in vivo reflectance [74] [75]. The scattering cross section of gold nanoparticles 
is extremely high compared to polymeric spheres of the same size (Figure 11), especially 
in the red. This property is crucial for development of contrast agents for optical imaging 
in living organisms because light penetration depth in tissue dramatically increases 
toward the red and near-infrared optical region. Another interesting optical property of 
metal nanoparticles is the increase in scattering cross section per particle when the 
particles aggregate (Figure 11, right). These changes produce a large optical contrast, in 
both the scattering cross section and the wavelength dependence of the scattering, 
between isolated gold particles and assemblies of gold particles. This increase in contrast 
improves the ability to image markers which are not uniquely expressed in diseased 
tissue, but are expressed at higher levels relative to normal tissue and to develop sensitive 
labeling procedures which do not require washing steps to remove single unbound 
particles. 
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Figure 2-11: Light scattering by suspensions of polystyrene 
spheres and gold nanoparticles with the same concentration 
(left). Comparison of scattering of isolated and agglutinated 
conjugates of 12 nm gold particles with EGFR antibodies 
(right). Published with permission from Real-Time Vital 
Optical Imaging of Precancer Using Anti-Epidermal Growth 
Factor Receptor Antibodies Conjugated to Gold Nanoparticles, 
Sokolov, K., Follen, M., Aaron, J., Pavlova, I., Malpica, A., 
Lotan, R., and Richards-Kortum, R., Cancer Research, 
63:1999-2004, May 1,2003. 
2.5.1.2 Synthesis 
We explore vital reflectance imaging using both gold and silver nanoparticles. 
The major focus is on development of agents based on gold because it is widely 
recognized that gold is biocompatible and can be used directly for in vivo applications. 
However, silver particles exhibit higher extinction coefficients and provide higher 
enhancement of the local EM field and of other effects associated with optical excitation 
of surface plasmon resonances [76]. Silver particles are not as stable or biocompatible as 
gold nanoparticles. This issue can be addressed by encapsulating silver particles inside 
an inert material such as silica coating [77]. This coating stabilizes particles and provides 
a well characterized surface for chemical immobilization of biomolecules. 
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Gold and silver colloid can be prepared from chloroauric acid (HAuCLO and silver 
nitrate (AgNOs) respectively by using a variety of reducing agents [78], [79], [80-82], 
[79, 83]. Preparation of highly uniform gold colloids with particle sizes ranging from 
about 10 nm to ca. 100 nm was demonstrated using sodium citrate reduction of 
chloroauric acid [80]. This colloid exhibits a single extinction peak ranging from 500 nm 
to about 540 nm depending on particle size. Sodium citrate reduction of silver nitrate 
results in a colloidal solution with about 35 nm diameter silver particles and a single peak 
at 410 nm [81, 82]. The distribution of silver particles is significantly broader; however 
the procedure is highly reproducible. Silver particles with narrower distributions and 
different diameters can be prepared using a starter hydrosol [79]. 
Figure 2-12: Scattering of silver nanoparticles with different 
sizes. Similar tuning of optical properties can be achieved 
with gold. 
Scattering properties of metal nanoparticles strongly depend on their size and 
shape. By changing sizes metal nanoparticles that exhibit different colors in reflected 
light can be produced (Figure 12). The strength and wavelength dependence of this 
scattering can be predicted using Mie theory. Additionally the position of the surface 
plasmon resonances of gold and silver can be significantly altered by using 
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nanocomposite materials described in [84, 85]. These materials consist of a dielectric 
optically inert core particle and an optically active gold shell and can be prepared in a 
variety of sizes. Another approach to tune optical properties of metal nanoparticles is 
based on template synthesis [86]. In one method metal nanoparticles of pyramidal shape 
with different sizes can be synthesized inside cavities formed by a dense monolayer of 
polystyrene beads on a flat substrate. After synthesis the nanoparticles can be removed 
from the surface by a simple one step procedure. The available variety of the synthetic 
methods allow optimization of scattering properties of contrast agents to take advantage 
of optical regions where tissue is most transparent depending on the degree of tissue 
penetration required. Another important venue is to use particles of different sizes 
conjugated to different probe molecules to achieve multi-color labeling. 
2.5.1.3 Conjugation 
There are a variety of possible strategies for preparation of conjugates of gold particles 
with cancer specific probe molecules. Well characterized conjugation protocols have 
been developed to prepare gold immunostains for electron microscopy [64, 65]. Briefly, 
the procedure is based on non-covalent binding of proteins at their isoelectric point (point 
of zero net charge) to gold particles. The complex formation is irreversible and very 
stable. In fact, the shelf life of the conjugates is so long that the most commonly used 
gold immunostains can be routinely purchased from major biochemical companies. 
Moreover, a variety of thiol terminated heterogeneous cross-linkers can be also used to 
covalently attach monoclonal antibodies to a gold surface. This approach is preferable for 
in vivo applications because it allows co-adsorption of other thiol terminated molecules 
such as polyethylene glycol (PEG) which is important to increase circulation of the 
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contrast agents in the body after systemic delivery. For vital imaging with contrast agents 
based on metal nanoparticles it is imperative to develop bioconjugates that have very low 
nonspecific binding and are not accumulated by the reticuloendothelial system. This 
issue is usually addressed by co-adsorbing polyethylene glycol (PEG) and probe 
molecules on the surface on nanoparticles. This strategy has been recently demonstrated 
in experiments on in vivo molecular specific imaging of embryogenesis using quantum 
dots [87] and in colloidal gold drug delivery system in live mice[88]. 
2.5.2 Quantum Dots 
2.5.2.1 Optical Properties 
Semiconductor nanocrystals with diameters smaller than the Bohr exciton 
diameter—on the order of 1-10 nm—exhibit size-dependent optical properties due to 
quantum confinement of electrons and holes, and are often referred to as "quantum dots". 
Fluorescence emission from the quantum dots can be tuned by size and composition to 
range from 400 nm to 2 |Lim with very narrow emission bandwidths of approximately 20-
30 nm [89, 90]. Quantum dots of different size that emit fluorescence at different 
wavelength can be excited at a single wavelength greater than their respective absorption 
edges. This provides a unique opportunity to do multi-color imaging experiments with a 
single excitation wavelength [91]. Despite the obvious advantages of quantum dots as 
compared to conventionally used fluorescence labels, their biological applications have 
been hampered by the low solubility of semiconductor materials which comprise the dots. 
Recently, new chemical strategies were proposed to make water soluble quantum dots 
that immediately resulted in exciting applications of quantum dots for biological imaging 
[63, 87, 92-95]. Comparison of quantum dots to one of the brightest fluorescent 
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molecules - Rhodamine 6G (R6G) - showed that the quantum dots are 20 times as bright, 
100 times as stable against photobleaching, and one-third as wide in spectral linewidth 
[63]. 
A variety of different types of quantum dots have been used for biological 
labeling: CdS for UV-blue, CdSe for the bulk of the visible spectrum, and CdTe for the 
far red and near infrared. Although the semiconductor dictates the spectral region where 
the emission occurs, the size of the particle can shift the wavelength - the absorption 
onset and emission shift to larger energy with decreasing size [95]. Our research has 
recently focused on CdTe quantum dots because the emission wavelengths fall within 
600-1300nm, the spectral region which has been demonstrated as best suited for 
biological imaging due to an increase in the penetration depth of light in tissue [96]. 
2.5.2.2 Synthesis and conjugation strategies 
A variety of semiconductor nanocrystals, or quantum dots, with relatively high 
quality optical properties can be produced using solution-phase methods [90, 97, 98]. The 
nanocrystal preparations must yield nanocrystals with a tight size distribution (to 
eliminate inhomogeneous broadening of optical properties), crystalline cores with few 
compositional and structural defects, and well-passivated surfaces. The most successful 
route to synthesizing semiconductor nanocrystals has been through arrested precipitation 
with subsequent size selective precipitation [90, 97]. Arrested preparation methods rely 
on binding bulky "inert" ligands to the particle surfaces during growth. Thiols have been 
used as capping ligands in a relatively general way since they adsorb to a wide variety of 
semiconductor materials. Other capping ligands include phosphines, amines, and 
carboxyl groups, depending on the chemistry of the inorganic material. The ligand 
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extending away from the particle surface determines the particle solubility. Particles can 
be functionalized with either hydrophobic (i.e., alkanes) or hydrophilic (carboxyl or 
amine groups for example) moieties. The nanocrystals are sufficiently stable that 
chemistry can be done to their surfaces. 
Figure 2-13: PL emission spectra of CdTe nanocrystals of 
increasing diameter (from 2 to 6 nm) left to right. The excitation 
wavelength was 540 nm for all of the nanocrystals. (Right) TEM 
image of a CdTe nanocrystals showing its internal crystallinity and 
spherical shape (Shieh, Saunders, and Korgel, unpublished data). 
CdTe quantum dots are synthesized using a modification of the organometallic 
method developed by Peng [99]. Briefly, cadmium oxide (CdO) and n-
tectradecylphosphonic acid (TDPA) are loaded with trioctylphosphine oxide (TOPO) into 
a reaction flask. The mixture is heated to 340° C under nitrogen to form a Cd-TDPA 
complex. As the mixture cools, a tellurium-trioctylphosphine (TOP) complex is injected. 
Spherical nanocrystals form quickly, resulting in monodisperse (Figure 13), highly 
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luminescent CdTe nanocrystals. The mixture is cooled and chloroform is injected to 
quench the reaction. Nanoparticles are isolated and cleaned by precipitation with ethanol. 
We showed that the size of the resulting nanocrystals is dependent on the temperature at 
which the TOP/tellurium is injected into the cadmium/HDPA/TOPO; as temperature of 
injections increases, the size of the nanocrystal increases but with a loss of quantum 
yield. The TOPO/TOP capping renders the quantum dots soluble in organic solvents, but 
not in aqueous environment. A post-synthesis ligand exchange is performed with 
mercaptopropionic acid (MPA) to render the quantum dots water soluble, and the 
carboxyl group extends into the solvent for use in subsequent linking to a targeting 
biomolecule using cross-linking agents similar to procedure described in [63]. In 
another approach, we carried out a partial ligand exchange with biotinylated PEG thiol; 
the avidin-biotin reaction can be used to add biotinylated targeting moieties (Figure 14). 
Alternatively, quantum dots can be encapsulated by silica and, then, a variety of 
silanization reagents can be used to introduce functional groups to silica surfaces for 
subsequent protein immobilization [94]. 
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Figure 2-14: Capped, aptamer targeted quantum dot. 
2.5.3 Smart Contrast Agents 
A number of enzyme-activatable fluorescent probes have been developed and 
tested for use in optical molecular imaging of cancer. In particular, a number of protease-
specific imaging probes have been developed to image cathepsin B [100], [101], [102] 
MMP-2 [103], [104], and caspase-3 [105]. In this approach, multiple residues of a near 
infrared fluorophore, typically Cy5.5, are coupled via a long circulating graft copolymer 
containing a cleavable peptide spacer that serves as cleavage sites for recognizing 
proteases. When the fluorophores are in close proximity, mutual energy transfer results 
in strong quenching of fluorescence. However, following enzymatic cleavage of the 
backbone, the fluorophores are released, resulting in strong detectable fluorescence. 
These enzyme sensing molecular beacons were used to image the presence of cathepsin-
B in dysplastic adenomatous polyps in a mouse model [106] and MMP-2 via a synthetic 
MMP-2 substrate peptide spacer [Gly-Pro-Leu-Gly-Val-Arg-Gly-Lys] [103]. In vitro, 
cleavage of the peptide spacer by MMP-2 releases dye molecules; fluorescence intensity 
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increases by 850% due to dequenching [103]. Activation could be blocked by MMP-2 
inhibitors. Activated probe could be detected in MMP-2 positive tumors implanted in 
nude mice 1 hour following IV injection, with a two-fold increase in fluorescence 
compared to MMP-2 negative tumors. 
Molecular beacons have been used to probe mRNA expression in living cells 
[107] This approach uses a single beacon consisting of an oligonucleotide probe capable 
of forming a stem-loop hairpin structure with a reporter fluorescent dye at one end and a 
quencher at the other end. In the absence of the target, the beacon is dark. When target 
RNA is present, the beacon opens and hybridizes; the quencher moves sufficiently far 
from the fluorophore resulting in bright emission [107]. While this approach provides a 
tool to probe gene expression in living cells, background fluorescence due to incomplete 
quenching limits sensitivity. A more sensitive approach uses a pair of molecular 
beacons, one with a donor and the other with an acceptor fluorophore, that hybridize to 
adjacent regions on a single mRNA target [108]. 
Thus, incomplete quenching limits the sensitivity of current molecular beacons 
for molecular imaging. Recent studies show that gold metal efficiently quenches the 
fluorescence of many fluorophores [109], and this approach has been used to provide 
efficient quenching in molecular beacons recently [110]. Gold nanoparticles quench the 
fluorescence of cationic polyfluorene with Stern-Volmer constants near 10n M"1, which 
is 9-10 orders of magnitude larger than small molecule dye-quench pairs. In addition, 
gold is immune to photobleaching problems associated with dye-based systems [109]. 
Dulkeith examined these effects for quenching lissamine fluorescence via colloidal gold 
as a function of particle diameter ranging from 2-60 nm [109]. Multiple lissamine 
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molecules were covalently attached to the gold via a 1 nra thioester spacer. Quenching of 
>99% of fluorescence was observed with 30 nm diameter gold particles. 
2.5.4 Delivery of Contrast Agents In Vivo 
Different delivery formulations may be required for different clinical applications, 
and optimizing these formulations is an important part of the design of a successful 
imaging strategy. To select therapy, to guide resection and to monitor response to 
targeted therapies in epithelial malignancies, topical application may be the route of 
choice, since the contrast agent can be applied directly to the tumor, the margin and 
tumor bed. To monitor molecular therapeutics of deep tumors and metastases, greater 
penetration may be required and thus systemic injection may be the optimal approach. 
2.5.4.1 Topical delivery 
Systemic delivery of imaging nanoparticles such as quantum dots have been 
recently described in a number of reports [111] [94] [112]. However, less data are 
available on topical delivery of contrast agents [74]. Here, we describe topical delivery 
formulations which combine mucoadhesive polymers and penetration enhancers. The 
goal is to (a) increase mucoadhesion of the nanoparticles, (b) increase penetration into the 
epithelial layer and (c) to preserve the specificity of the contrast agents for cancer 
biomarkers. Below, we give three examples of polymer formulations that appear 
promising for topical delivery of contrast agents. 
Polycarbophil-PVP is based on a combination of mucoadhesive polycarbophil (1-
3% w/v, B.F. Goodrich) and 1-3% polyvinylpyrrolidone, (PVP K-90, BASF). 
Polycarbophil is a water in-soluble (but swellable) polymer that is highly mucoadhesive 
and has been used in vaginal and topical drug delivery [113-120], specifically for the 
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delivery of progesterone [e.g. Replens, Columbia Laboratories Inc.]. PVP is a widely 
used excipient in topical formulations [e.g. Povidone] and could enhance the permeability 
of the mucosal surface. 
2.5.4.1.1 Carbopol-PVP 
Carbopol (Noveon Inc., or Polymer Sciences, NJ), a water-soluble polymer, along 
with PVP as a permeation enhancer. Carbopol (polyacrylic acid) is a highly bioadhesive 
polymer that has been shown to adhere strongly with different mucosal surfaces [121-
127]. Low concentration should be used to ensure that the formulation can be washed 
away before imaging and to ensure adequate diffusion of particles out of the formulation 
and into the mucosa. 
2.5.4.1.2 Chitosan-Carboxymethylcellulose 
Chitosan is a biocompatible polymer that has been widely used in drug delivery 
and topical wound healing applications. Chitosan, a highly mucoadhesive polymer [128-
131], increases para-cellular permeation of drugs, peptides and proteins across the 
mucosal epithelium [132-138] and is widely used in nasal and oral delivery as well as in 
some studies for vaginal delivery [139, 140]. A 0.1-0.5% solution of chitosan (MW 
-290,000) containing 5% carboxymethyl cellulose (a viscosity enhancer) would provide 
an appropriate solution for the topical application of contrast agents. 
Both carbopol and polycarbophil are widely used in mucosal formations; however 
neither has been previously used for nanoparticle delivery. The third approach differs 
from the first two because of the permeation enhancing properties of chitosan. These 
delivery formulations have to be still thoroughly tested in tissue cultures and animal 
experiments before transition to clinical testing. 
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2.5.4.2 Systemic delivery 
One of the promising approaches to formulating nanoparticles for systemic 
delivery is the use of polyethylene glycol (PEG) functionalized nanoparticles where the 
distal end of the PEG is conjugated to the targeting ligand. This design ensures 
appropriate targeting of the nanoparticles without steric hindrance while at the same time 
providing "stealth" properties to the particles for prolonged systemic bioavailability. This 
can be achieved using a heterobifunctional PEG carrying a thiol group at one end and an 
N-hydroxysuccinimide (NHS) ester at the other end (SH-PEG-NHS, Nektar 
Therapeutics, MW 3400). First the SH-PEG-NHS is reacted with the targeting antibody 
or aptamer (carrying a primary amine end group) under reducing condition (i.e. presence 
of 0.1 mM Dithiotrietol, pH 8.5, Phosphate buffer) to generate SH-PEG-ligand. This 
ensures that the SH groups do not form disulfide bonds during the reaction. Then, SH-
PEG-ligand is conjugated directly to the gold nanoparticles or is attached to the surface of 
quantum dots using a ligand exchange reaction. Another approach has been reported by 
Nie [92] where amphiphilic triblock copolymers (polybutacrylate-polyethacrylate-
polymethacrylic acid) are used as a micellar coating on quantum dots for in vivo 
delivery. 
2.6 Molecular Specific Optical Imaging 
2.6.1 Metal Nanoparticles 
First applications of silver and gold nanoparticles as scattering contrast agents for 
in vitro biological assays were reported in [72] [73]. It was demonstrated that scattering 
signal from the single nanoparticles can be millions of times brighter than signal from 
individual fluorescent molecules that can enable development of ultra-sensitive immuno 
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and DNA probe assays. Our group has been working on development of contrast agents 
based on gold nanoparticles for detection of cancer biomarkers in living cells [74] [75]. 
In this section we demonstrate molecular specific imaging of EGFR using gold 
bioconjugates with anti-EGFR monoclonal antibodies. In these studies, gold 
nanoparticles with ca. \2 nm in diameter were used. Our data show that gold conjugates 
are stable in biological samples and do not exhibit non-specific aggregation. 
2.6.1.1 Metal Nanoparticles and EGFR. 
Figure 15 shows confocal reflectance and combined transmittance/reflectance 
images of SiHa (human cervical cancer cell line) cells labeled with anti-EGFR/gold 
conjugates. Labeling predominately occurs on the surface of the cytoplasmic membrane, 
specifying the transmembrane localization of EGFR. The intensity of light scattering 
from the labeled cells is ca. 50 times higher than from unlabeled cells. Therefore, 
unlabeled cells cannot be resolved on the dark background. In fact, light scattering from 
the labeled cells is so strong that it can be easily observed using low magnification optics 
and an inexpensive light source such as a laser pointer [74]. No labeling was observed 
with nonspecific monoclonal antibodies. We observed heterogeneous labeling of SiHa 
cells in suspension. Heterogeneity of protein expression in cell lines is not uncommon 
and has been described before in the case of EGFR [141]. We determined that ca. 5xl04 
gold conjugates are bound per cell. This number correlates very well with our 
measurements of the amount of EGFR per SiHa cell using flow cytometry that yielded 
5xl04 receptors per cell. 
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Figure 2-15: Confocal reflectance (A) and combined reflectance/transmittance (B) 
images of labeled SiHa cells. Scattering from gold conjugates is false-colored red (scale 
bar: ca. 20 mm). Published with permission from Real-Time Vital Optical Imaging of 
Precancer Using Anti-Epidermal Growth Factor Receptor Antibodies Conjugated to Gold 
Nanoparticles, Sokolov, K., Follen, M., Aaron, J., Pavlova, I., Malpica, A., Lotan, R., and 
Richards-Kortum, R., Cancer Research, 63: 1999-2004, May 1, 2003. 
We extended our work using anti-EGFR gold conjugates to label organ cultures of 
normal and neoplastic cervical tissue. Cultures were incubated in a solution containing 
contrast agent, then the excess of the contrast agents was removed and the specimens 
were imaged with reflectance based confocal microscopy. The bright "honey-comb" like 
structure of labeled cellular cytoplasmic membranes of closely spaced cells can be easily 
seen in a section of an abnormal biopsy (Figure 16, top A). No labeling of the normal 
biopsy can be seen when the sample is imaged under the same acquisition conditions 
(Figure 16, top B). Anti-EGFR/gold conjugates did not bind to the stromal layer of 
cervical biopsies. 
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Figure 2-16: Squamous cervical epithelium labeled with 
anti-EGFR antibodies/gold nanoparticles conjugates: (A) 
abnormal and (B) normal epithelium obtained under the 
same acquisition conditions. Published with permission 
from Real-Time Vital Optical Imaging of Precancer Using 
Anti-Epidermal Growth Factor Receptor Antibodies 
Conjugated to Gold Nanoparticles, Sokolov, K., Follen, 
M , Aaron, J., Pavlova, I., Malpica, A., Lotan, R., and 
Richards-Kortum R., Cancer Research, 63:1999-2004, 
May 1, 2003. Squamous oral epithelium labeled with anti-
EGFR biotinylated antibodies and Alexa Fluor 660 
fluorescent dye/streptavidin complex: (C) clinically 
abnormal (moderate dysplasia), (D) clinically normal. 
2.6.1.1.1 Comparison of gold and fluorescent labeling 
We conducted studies of EGFR labeling in cervical biopsies using gold anti-
EGFR conjugates [74] and in oral cavity biopsies using fluorescent dyes [142]. The 
cervix and oral cavity are both covered by a squamous epithelium which undergoes very 
similar progressions from normal to malignant stages. The level of EGFR expression of 
cancerous cells is very similar in both epithelia [143, 144]. Therefore, the labeling results 
obtained in these two studies can be compared. Figures 16 shows images of 
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abnormal(moderate dysplasia)/normal pairs of human squamous epithelium labeled using 
anti-EGFR monoclonal antibodies conjugated with 12 nm gold nanoparticles (Figure 16, 
top) and anti-EGFR monoclonal antibodies complexes with Alexa Fluor 660 streptavidin 
(Figure 16, bottom). The ratio of signal intensity between the normal and the abnormal 
biopsies is ca. 15 and ca. 3 in the case of gold nanoparticles and the fluorescent dye, 
respectively. It is important to note that two washing steps in IX PBS had been carried 
out before the fluorescent images were obtained. No washing steps were required for the 
reflectance imaging with gold nanoparticles. 
High contrast imaging with gold nanoparticles without intermediate washing steps 
is possible because nanoparticles undergo significant changes in optical properties when 
they form closely spaced assemblies on the surface of malignant cells. In assemblies the 
total scattering cross section scales with N , where N is the number of nanoparticles in 
the assembly. In addition, electrodynamic coupling between the scattered fields of 
adjacent nanoparticles results in a simultaneous red-shift of the resonance scattering 
spectra (Figure 11, right) [74]. This shift can be used to tune the excitation wavelength 
for detection of labeled cells in the presence of single unbound gold bioconjugates. 
2.6.1.1.2 Signal intensity: gold nanoparticles vs. fluorescent dye 
The signal intensity of the abnormal biopsy labeled using gold bioconjugates 
(Figure 16, top A) is ca. 80 times higher than the signal collected from the fluorescently 
labeled specimen (Figure 16, bottom). It has been reported that the cross section of 
scattering from a 50 nm gold particle is approximately a million-fold larger than the 
absorption or emission cross sections of the brightest known organic molecules or even 
quantum dots [61] . The scattering signal can be dramatically increased because the 
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scattering cross-section of gold nanoparticles increases as the sixth power of their radius. 
This enables a very simple way of changing signal strength which is not that simple in the 
case of fluorescent dyes or quantum dots. Gold nanoparticles are also immune to 
photobleaching and do not undergo any photochemical reactions which can be potentially 
toxic. 
2.6.1.1.3 Imaging of metal nanoparticles 
Imaging of cancer cells labeled with gold nanoparticles can be perfomed using 
microscopic detection with wide field illumination (not shown) or with scanning confocal 
microscope (Figures 15 and 16). The detection can be also carried out using macroscopic 
wide-field of view CCD cameras with a broad band white light source. The macroscopic 
detection can be optimized using illumination through band-pass filters in red optical 
region where the labeled cells have increased scattering. 
2.6.1.1.4 Safety of Metal Nanoparticles for In Vivo Use 
Contrast agents based on gold nanoparticle antibody conjugates have the potential 
for in vivo use, with topical or systemic delivery. The inherent biocompatibility of gold 
implies that they can be used directly in vivo without the need for protective layer growth. 
In fact, long term treatment of rheumatoid arthritis utilizes gold [145] (up to a cumulative 
dose of 1.2-1.8 g/year for up to 10 years). It has been shown that prolonged treatment 
with gold salts leads to formation of gold crystals and their deposition in lysosomes of 
macrophages [146-148]. This condition is called chrysiasis and it was first described in 
1928. Chrysiasis is the development of a blue-grey pigmentation in skin. The effects of 
this condition have no serious pathological significance and are considered to be purely 
cosmetic. Chrysiasis can develop only after a threshold, equivalent to 20 mg/kg gold 
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content or after few grams of gold are administered through i.v. or other type of treatment 
[146]. We anticipate that between a few hundred micrograms to a few milligrams of gold 
would be required for a diagnostic procedure. This is thousands times less than the 
threshold for any types of side effects detected in clinical practice. Humanized 
antibodies, where a mouse antibody-binding site is transferred to a human antibody gene, 
are much less immunogenic in humans [149], and many humanized antibodies are 
currently in clinical trials. Since 1997, the FDA has approved more than 10 monoclonal 
antibody based drugs, including Herceptin for metastatic breast cancer therapy [149, 
150]. Gold nanoshells are also a focus of a new minimally invasive thermal treatment of 
cancer [14]. Pre-clinical studies of the technology in animals have shown promising 
therapeutic effect as well as biocompatibility and lack of any cytotoxicity associated with 
the particles. 
In summary, metal nanoparticles are a new class of very bright contrast agents 
which exhibit a number of unique optical properties including dramatic non-linear 
increase in scattering cross-section per particle and red shift in plasmon resonance 
frequency (color change) when the particles form closely spaced assemblies. These 
properties account for the higher contrast observed in the imaging of normal/abnormal 
human tissue using gold bioconjugates as compared to fluorescent labeling (Figure 16). 
2.6.2 Quantum dots 
Recently, the first in vivo applications of quantum dots were demonstrated [87, 
94] [62]. In [94] quantum dots conjugated with peptides specific for normal lung or 
tumor blood vessels, or for tumor lymphatic vessels were i.v.-injected into tumor bearing 
mice. Specific targeting of lung or tumor vasculature using peptide-coated quantum dots 
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was demonstrated in this study. No acute toxicity associated with i.v. administration of 
the quantum dots was observed even after 24 hours of circulation. In another study 
quantum dots were solubilized for biological in vivo imaging by encapsulation inside 
phospholipid block-copolymer micelles [87]. The encapsulated dots were microinjected 
into individual cells at early-stage Xenopus embryos. The authors followed development 
of the labeled cells because the dots were confined to progeny of the injected cells. The 
encapsulated quantum dots do not exhibit any biological activity and are non-toxic for 
embryos at the levels of ca. 2 x 109 dots/cell. These studies suggest that the encapsulated 
nanoparticles are stable in vivo. 
2.6.2.1 Aptamer targeted quantum dots 
Recently specific labeling of prostate cancer cells using aptamer targeting of CdTe 
quantum dots was demonstrated [151]. CdTe 3 nm diameter nanocrystals were 
synthesized, then rendered water-soluble and biocompatible by ligand exchange, first 
with mercapto-propionic acid (MPA) and then partial ligand exchange with thiolated and 
biotinylated PEG. The biotinylated PEG-quantum dot complex was then incubated with 
avidin. An anti-prostate specific membrane antigen (PSMA) aptamer was biotinylated 
and affixed to the avidin-coated quantum dots. The aptamer-quantum dot conjugates 
were then used to label either LNCaP cells, a prostate tumor line that overexpresses 
PSMA on its surface, or PC3 cells, a line that has little PSMA on its surface. As can be 
seen in Figure 17, the quantum dot conjugates specifically light up the LNCaP cells. No 
emission was seen in PC3 cells. 
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Figure 2-17: Quantum dot conjugates targeted against PSMA (A) and 
untargeted (B). 
2.6.2.2 Biocompatibility and cytotoxicity of quantum dots 
There is significant concern and uncertainty about the biocompatibility and 
cytotoxicity of semiconductor nanocrystals. In bulk form, the Cd-based Group II-VI 
semiconductors, CdE (where E is S, Se and Te), and the Group III-V semiconductors 
(such as InAs and InP) are well known to be acutely toxic and carcinogenic [152] [153] 
[154]. However, nanocrystals of these materials are coated with organic ligands and 
often with inorganic shell materials like silica. Some researchers have not observed any 
indications of toxicity in live cell imaging studies and have suggested that semiconductor 
nanocrystals will not be toxic [94] [62, 155]. Recent studies, however, showed that the 
nanocrystals can indeed be acutely toxic under certain situations, primarily as a result of 
heavy metal (i.e., Cd +) leaching from the nanocrystal core [156] [157]. In long-term in 
vivo applications, the toxicity limits become more important and more rigorous as 
exposure times are extended. The inherent toxicity is still somewhat of an open question, 
as both Drefus, et al. [157] and more recently, Kirchner, et al. [156] have shown that 
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under certain circumstances, effective passivation of the nanocrystals can indeed render 
semiconductor nanocrystals non-toxic. The situation is somewhat complicated, however, 
as Kirchner, et al.'s [156] recent study proved that the capping ligand chemistry and cell 
binding efficiency can be equally as important as the inorganic core chemistry in terms of 
cytotoxicity or biocompatibility. These results are consistent with those of Dubertret, et 
al. [87], who observed robust biocompatibility with ZnS-overcoated CdSe nanocrystals 
encapsulated in phospholipids micelles when injected into Xenopus embryos for lineage-
tracking experiments in embryogenesis. 
The general guidelines for reduced cytotoxicity that have emerged from recent 
studies are: (1) inorganic shells like silica or ZnS can greatly reduce cytotoxicity; (2) 
PEGylation can greatly reduce cytotoxicity by inhibiting intracellular non-specific uptake 
and (3) particle aggregation on the cell surface leads to rapid cell poisoning [156]. These 
considerations must be taken into account in the design of quantum dots for in vivo 
molecular imaging. 
2.7 Conclusions 
Development of optical molecular imaging approaches for in vivo monitoring of 
therapeutic target of cancer is a multi-disciplinary problem that requires the combination 
of expertise in the fields of biomedical optics, nanotechnology, molecular specific 
targeting, in vivo delivery, and cancer molecular biology. In this chapter, we presented 
the synergy of these diverse scientific areas in development of molecular specific 
imaging which is based on two emerging types of optically active contrast agents - metal 
nanoparticles and quantum dots. The cocktail of presented contrast agents can provide 
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the ability to monitor major hallmarks of cancer including: (1) self-sufficiency in growth 
signals (EGFR and EGF), (2) evasion of programmed cell death (anionic phospholipids), 
(3) tissue invasion and metastasis (MMPs) and (4) sustained angiogenesis (VEGF and its 
receptors). 
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CHAPTER 3: PHOTOSTABILITY OF QUANTUM DOTS WITH 
AMPHIPHILIC-BASED PASSIVATION STRATEGIES1 
3.1 Abstract: 
Quantum dots (QDs) have many appealing properties for biological fluorescence 
imaging, but exhibit photostabilities that are dependent upon surface passivation to 
minimize susceptibility to oxygen and light. Here, through spectroscopy and imaging 
techniques, we compare the photostability of micelle-encapsulated QDs with QDs 
passivated with either crosslinked amphiphilic polymers or crosslink-free amphiphilic 
polymers. Both crosslinked and crosslink-free amphiphilic polymer passivation 
strategies produced QDs with high photoluminescence stability when exposed to light 
under ambient conditions. In contrast, micelle encapsulation resulted in QDs with 
photoluminescence emission levels that were highly sensitive to both light exposure and 
oxygen, exhibiting a reduction of up to 70% in photoluminescence intensity within 
twenty minutes of exposure. With the addition of reducing agents, the 
photoluminescence level of the micelle-encapsulated QDs was significantly stabilized. 
We conclude that amphiphilic polymers provide coatings with considerably higher 
integrity and stability than micelle encapsulation, reducing the QD's sensitivity to oxygen 
and light, both of which are relevant factors in biological imaging applications. 
1
 This chapter has been published previously in D.L. Nida, N. Nitin, W.W. Yu, V.L. Colvin, and R.R. 




Quantum dots (QDs) have emerged as attractive alternatives to small organic 
fluorescent dyes and have been used in a wide range of biological applications [62, 93, 
95, 156-160]. Their unique optical properties provide several advantages over organic 
fluorophores for biological imaging [161], including broad excitation spectra coupled 
with narrow, tunable emission spectra, high photoluminescence quantum efficiency, and 
high resistance to photobleaching [95] [162]. Despite these advantages, there are 
challenges to the successful application of QDs in biological imaging. Optical probes for 
biological imaging must exhibit low non-specific interactions, high resistance to 
photobleaching, colloidal stability, and be small, biocompatible, and water soluble. All 
of these desirable properties rely on an effective surface passivation strategy, which 
should also enable the conjugation of additional biomolecules for directed targeting. 
Researchers have encountered difficulties in developing QD surface passivation coatings 
that simultaneously satisfy all of the above criteria. Published methods in the literature 
include the use of monothiolated [63, 96, 163] or bidentate thiols [164], silane [95, 165], 
encapsulation within amphiphilic polymers [87, 166, 167], and the direct attachment of 
proteins or peptides [168-171]. Comprehensive reviews on QDs are available that 
describe further details of surface coatings and capping strategies [62, 164]. 
Amphiphilic-polymer coated QDs have been shown to perform well both in cell 
labeling and in vivo studies, with decreased aggregation and fluorescence loss [172]. 
Interdigitation of the QD's native organic capping groups with the hydrophobic groups 
on the amphiphilic polymer allows the original organic coordinating ligands to remain 
intact on the QDs. As a result of the strong hydrophobic interaction between the organic 
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coordinating ligands on the QD and the polymer hydrocarbon chain, a strongly bound 
structure is created that resists hydrolysis and enzymatic degradation [172]. This surface 
passivation method is superior to methods requiring direct interaction with surface 
ligands (such as ligand exchange), because the QD's original quantum yield is retained 
[166, 167]. Of importance for biological applications, is the fact that the hydrophilic 
groups on the amphiphilic polymer impart water solubility to the encapsulated QD. In 
addition, different chemical components can be incorporated into the polymer chain to 
increase biocompatibility (such as PEG), to allow further conjugation (such as amines, 
carboxyls, etc.), or to facilitate crosslinking. In principle, crosslinking of the amphiphilic 
coating may be advantageous, in order to create a more stable structure with reduced 
sensitivity to oxygen. 
A simple variation of the amphiphilic polymer-based passivation strategy 
involves the encapsulation of QDs within a phospholipid micelle containing PEG. 
Similar encapsulation methods have been used in drug delivery systems to deliver 
hydrophobic molecules [173], and more recently for QDs [87]. The micelle 
encapsulation method utilizes an amphiphilic PEG-phospholipid with a hydrophobic 
region that interacts with the QD surface, and a hydrophilic region that renders the final 
coated QD water-soluble. The hydrophilic region can incorporate additional functional 
groups such as biotin or amine, for further conjugation to an antibody or aptamer for 
biological targeting. Micelle-encapsulation has several appealing features, including 
technical simplicity (no crosslinking step), relative ease of subsequent bioconjugation, 
and biocompatibility. In addition, the process results in QDs of ~ 15 nm diameter, 
potentially enhancing access to biological targets and intercellular compartments [174]. 
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In comparison, existing amphiphilic polymer-based techniques yield particle diameters of 
~30nm[175, 176]. 
In previous studies attempting to quantitatively evaluate a particular passivation 
strategy, quantum yield (QY) has been used as the primary figure-of-merit, with most 
researchers determining the QY with, and without the passivating ligand [165, 170, 177]. 
Researchers have additionally used parameters including cytotoxicity [157], 
luminescence intensity over time [170, 174], and colloidal stability across a range of pH 
[92, 174]. In this study, we investigate three biologically-relevant QD passivation 
strategies. In all experiments, we use photoluminescence intensity as a quantifiable 
measure of QD photostability, and test QDs under conditions of varying exposure to light 
and oxygen using spectroscopy and confocal imaging. 
3.3 Materials and Methods: 
3.3.1 Surface passivation chemistry 
In this section, we describe the details of the three QD surface passivation 
methods compared in this study. The first system is a commercially-available 
crosslinked amphiphilic-polymer coated QD (which we will term cAmp QD) (Invitrogen, 
CA), representing the gold standard against which the two other surface passivation 
strategies will be compared. The second system is a crosslink-free amphiphilic-polymer 
coated QD (Amp QD) developed by Yu et al. [175, 178, 179] which we use as an analog 
to the commercially-available cAmp QD, to isolate the effects of crosslinking polymers. 
Third, we investigate a simple micelle-encapsulation system (p-micelle QD) based upon 
phospholipid PEG biopolymers. The use of p-micelle encapsulation allows comparison 
with an approach to QD preparation that is both simple, and results in reduced particle 
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size compared to the standard coating approaches developed using synthetic amphiphilic 
polymers. 
3.3.2 Amphiphilic crosslinked-polymer coated quantum dots (cAmp QD) 
Quantum dots with an amphiphilic crosslinked polymer coating were purchased 
from a commercial vendor (QDOT 585 ITK, Invitrogen, CA). 
3.3.3 Amphiphilic-polymer coated quantum dots (Amp QD) 
Monodisperse QDs were synthesized and coated with the amphiphilic polymer 
poly(maleic anhydride-alt-1-octadecene) (PMAO, MW = 30,000-50,000) that was 
reacted with PEG (MW 6000) to form a PMAO:PEG amphiphilic polymer as previously 
reported [175]. 
3.3.4 Micelle encapsulation of quantum dots (p-micelle QDs) 
Trioctylphosphine oxide (TOPO) capped CdSe/ZnS quantum dots (Maple-red 
orange, 620 nm) in toluene were purchased from Evident Technologies (Troy, NY), and 
methods employed for micelle encapsulation were similar to those previously published 
[87]. Exposure to light was avoided throughout the entire preparation. Toluene present 
in the QD solution (100 uL of 4.2 nM) was removed in a Biichi Rotavapor R200 (Biichi, 
Switzerland) at 20 millibar for one hour. Dried quantum dots were then resuspended in 
5 ml chloroform with 1ml of lOmg/ml l,2-Distearoyl-sn-Glycero-3-
Phosphoethanolamine-N-[biotinyl(polyethylene glycol) 2000] (Avanti Polar Lipids, 
Huntsville, AL). This mixture was then dried at 20 millibar in the Biichi Rotavapor for 3 
hours, then resuspended in 1 ml of deionized filtered water that had been nitrogen 
bubbled for 3 hours to remove oxygen. Micelles were formed upon the addition of the 
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water, as evidenced by their stability in water. This micelle solution was packed with 
nitrogen and stored at 4 °C overnight. 
3.4 Measurement techniques 
3.4.1 Dynamic light scattering (DLS) measurements 
Light scattering measurements of the three differently passivated QD species were 
taken using a Brookhaven 90 Plus particle size analyzer (Brookhaven Instruments 
Corporation, NY), at three different concentrations to ensure accurate size determination. 
All samples were filtered using Anotop 0.2 urn inorganic syringe filters (Whatman, UK) 
and measurements acquired at room temperature. Data were fit using either non-
negatively constrained least squares Contin (regularized) or non-negative least squares 
(NNLS, multiple fit), depending on the expected QD size distribution using Brookhaven 
Dynamic Light Scattering software. 
3.4.2 Transmission electron microscopy (TEM) 
P-micelle QDs were negatively stained with a 1% solution of ammonium 
molybdate in water, allowing the phospholipid micelle to be visualized under TEM. 
Following staining, the solution was deposited on a 200-mesh copper TEM grid (Ted 
Pella, CA) and immediately imaged on a JEOL JEM - 1010 Transmission Electron 
Microscope. 
3.4.3 Photoluminescence measurements 
Photoluminescence measurements were performed using a spectrofluorimeter 
(SPEX Fluorolog 2, Horiba Jobin Yvon, NJ). All samples were optically dilute 
(OD < 0.05) at the 400 nm illumination wavelength, with emission spectra collected in 
the range from 410 nm to 790 nm using a 1 mm slit width. The illumination power was 
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measured to be 77 uW at the sample location, and the spectrum from an aqueous solvent 
blank was subtracted from all QD spectra to correct for solvent emission. 
The effect of light exposure on QD photoluminescence was tested by acquiring 
emission spectra with either constant illumination throughout the entire duration of the 
experiment, or illumination only during the time required for acquisition of each 
spectrum. During these measurements, samples were contained in quartz cuvettes with 
no attempt to restrict QD exposure to oxygen. The effect of oxygen on QD 
photoluminescence was tested by embedding an optically dilute QD solution in 10% 
gelatin, therefore reducing oxygen diffusivity to the QDs. These embedded samples were 
subjected to continuous illumination in the spectrofluorimeter, and emission spectra 
acquired at the same time points as previous experiments on QDs in solution. To further 
investigate the role of oxygen in the loss of QD photoluminescence, two different 
reducing agents were added to QDs in solution. Either 5.6 mM of 2-mercaptoethanol 
(PME) or 5.6 mM of Tris(2-carboxyethylphosphine hydrochloride) (TCEP) was added, 
after bubbling with nitrogen to reduce the oxygen. Selection of these reducing agents 
was motivated by the fact that PME contains a thiol group while TCEP does not, 
allowing the mechanism of interaction between the QD and reducing agent to be 
investigated. Again, emission spectra were acquired for QDs in solution with each 
reducing agent, under constant illumination as described above. In experiments 
involving reducing agents, measurement time points were extended to allow the reducing 
agent to diffuse to the QD surface, and potentially passivate any open surface states. 
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3.4.4 Confocal microscopy 
A laser scanning confocal microscope (LSM 510, Zeiss, Germany) with an argon 
line (488 nm) and a 560 nm long-pass emission filter was used to acquire images of QDs 
with each of the three tested surface coatings. QD samples prepared with matched 
optical densities were deposited onto a thin layer of 10% gelatin on conventional 
microscope slides. Three images were taken and then the sample was exposed to 500 
iterations of light (approximately two minutes) within a pre-defined region of interest 
(ROI). During imaging, QD samples were illuminated with both 458 nm and 488 nm 
laser lines with a total power of 0.54 mW at the sample plane to induce photobleaching. 
Three images were taken after exposure to the light. We have previously found that most 
fluorophores bleach within 100-200 iterations under these experimental conditions. Bar 
graphs were constructed to represent the average intensity of the three images within the 
ROI before and after being subjected to the 500 iterations of light. 
3.5 Results 
Dynamic light scattering measurements and transmission electron microscopy 
imaging were performed to evaluate the coated QD size, and confirm micelle 
encapsulation. Micelle encapsulation repeatedly produced -15 nm diameter particles 
compared to the ~ 30 nm diameter amphiphilic coated QDs. The colloidal stability of 
these p-micelle QDs (based on size and ability to remain suspended, aggregate free in 
aqueous solution) additionally indicated that the QDs were well encapsulated (data not 
shown). 
The results of photoluminescence measurements for each of the three coated QDs 
in suspension are shown in Fig. 1, corresponding to conditions of continuous 
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illumination, and unrestricted presence of oxygen. Data points represent the emission 
intensity at the peak wavelength, normalized to the level measured at the onset of 
illumination. Under these conditions, p-micelle QDs lost approximately 70% of their 
photoluminescence within the first 20 minutes of illumination, whereas emission from 
both surface coating strategies employing amphiphilic polymers was reduced by only 7% 
(Amp QDs) and 3% (cAmp QDs). After 4 hours, emission from both polymer-coated 
QDs remained high, with Amp QD photoluminescence at 87%, and cAmp at 91% of their 
initial levels. 
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Figure 3-1: Normalized emission intensity over time for QD solutions subject to 
continuous illumination. 
To investigate the loss of photoluminescence from p-micelle QDs demonstrated in 
Fig. 1, these QDs were further tested to elucidate the mechanisms behind their sensitivity 
to light and oxygen. To test the oxygen sensitivity of the micelle encapsulation strategy, 
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p-micelle QDs were embedded in 10% gelatin, resulting in three effects: 1) reduced 
oxygen diffusivity 2) reduced micelle dissociation, and 3) reduced Brownian motion. 
Attenuation of light due to the gelatin substrate was found to be minimal. In Fig. 2(a), 
photoluminescence intensity measurements are displayed for p-micelle QDs embedded in 
gelatin, alongside data for the same QDs in aqueous suspension, both under continuous 
illumination. The loss of photoluminescence was reduced for the gelatin-embedded QDs, 
dropping by 40% of the initial level after 50 minutes, compared to an 80% reduction for 
QDs in suspension. 
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Figure 3-2: Normalized emission intensity of p-micelle QDs: (a) embedded in 10% 
gelatin versus in aqueous solution (b) in solution with reducing agent ((3ME or TCEP) 
versus in aqueous solution (c) under continuous illumination or illumination only upon 
spectra acquisition. 
The effects of the presence of PME and TCEP reducing agents on p-micelle QD 
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resulted in an increase in photoluminescence under continuous illumination. An increase 
of 16% in photoluminescence signal was observed in the presence of PME, which 
continued to increase at 2 hours, compared to a relatively stable increase of 9% observed 
with TCEP over the same time period. 
Figure 2(c) presents the photoluminescence intensity from a solution of p-micelle 
QDs over the 2 hour time course when subjected to light only upon spectra acquisition, 
alongside the data for continuous illumination. While the reduction in 
photoluminescence was comparable under both conditions over the first 10 minutes, the 
p-micelle QDs maintained in dark conditions retained an emission level that was 
consistently higher than continuously-illuminated QDs at all subsequent time-points. 
After 2 hours, samples maintained in dark conditions, and illuminated conditions 
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Figure 3-3: Quantification of photoluminescence loss associated with photobleaching in 
p-micelle QDs and cAmp QDs during confocal imaging. Bar graphs represent three-
image average fluorescence intensity before and after exposure to 500 iterations of light. 
Following the spectroscopic studies presented in Figs. 1 and 2, the photostability 
of cAmp QDs and p-micelle QDs were tested using confocal fluorescence microscopy, of 
relevance in biological imaging applications. The measured intensity values within the 
pre-defined regions-of-interest are presented, averaged over three consecutive images in 
each case (Fig. 3). The cAmp QDs do not exhibit an appreciable loss of signal over the 
time course of this measurement, while the average signal from the p-micelle QDs was 
reduced to 50% of its original level. 
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3.6 Discussion 
The photoluminescence properties of QDs are highly sensitive to factors affecting 
their surface states. A passivation strategy is needed to shield oxygen molecules from 
interacting with the QD, thereby inhibiting photooxidation [170]. The results of Smith et 
al. [176] suggest that the amphiphilic polymer, poly(methyl methacrylate)-polyethylene 
oxide (PMMA-PEO) can serve as an effective barrier to oxygen diffusion. In this study, 
we further investigated the effectiveness of amphiphilic polymers and micelle 
encapsulation in preserving the photoluminescent emission intensity from QDs. 
Measurements of photoluminescence intensity over time demonstrated that 
p-micelle coated QDs have relatively low photostability compared to both crosslinked 
and crosslink-free amphiphilic polymer coated QDs (Fig. 1). In the case of crosslinked 
amphiphilic polymers, the protective coating is permanently associated with the QD, due 
to the existence of crosslinking agents and extensive hydrophobic regions. However, 
since even the crosslink-free coating exhibited essentially identical photostability to the 
crosslinked system, we hypothesize that the dominant factor that confers photostability is 
not the existence of crosslinking, but the degree of hydrophobic packaging on the 
polymer. The PMAO: PEG coating has an extensive network of hydrophobic branches 
extending from a single polymer backbone. This feature allows the PMAO: PEG coating 
to form multivalent bonds with the hydrophobic regions on the QD surface, resulting in 
highly stable association. In contrast, the p-micelle coating does not exhibit extended 
regions of hydrophobicity, and therefore associates with the surface in a monovalent 
fashion. We expect that these differences in bond valency lead to significant differences 
in association and mobility of the polymer coating. Micelle structures have previously 
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been shown to be dynamic in nature, with lipid exchange rates on the order of 
milliseconds [180]. It is this behavior that allows the surface of the micelle-coated QD to 
be exposed to oxygen. In addition, the hydrophobic region of the p-micelle coating is 
significantly smaller (3,000 MW) than that of the amphiphilic polymer coatings (30,000-
50,000 MW) [175], further reducing the degree of protection against oxygen diffusion to 
the QD surface. 
When p-micelle coated QDs were embedded in gelatin, the decrease in 
photoluminescence was less pronounced than in solution (Fig. 2(a)). This effect could 
arise from one or both of a decrease in oxygen diffusivity, and tighter QD packing when 
embedded in gelatin. When micelles were dried onto a glass slide, we also observed an 
improvement in stability of emission intensity over time when imaged under confocal 
fluorescence microscopy (data not shown). By creating a more compact, static micelle 
structure through either drying or embedding in gelatin, we inhibited oxygen diffusion to 
the QD surface, relative to QDs in solution where the micelles are fluid and dynamic. 
The addition of either of two reducing agents stabilized and actually increased PL 
of p-micelle QD suspensions over time (Fig. 2(b)). We believe this effect to be due to the 
reduction of oxygen within the system by the reducing agent. Significantly, the reducing 
agent with thiol present (PME) generated a higher photoluminescence intensity than a 
reducing agent without thiol (TCEP). This increase in photoluminescence is consistent 
with Wu et al.'s use of the thiol-posessing anti-fade medium, Vectashield, with Qdot 
streptavidin 608 (encapsulated in an amphiphilic polymer). A 104% increase in emission 
intensity was measured when the anti-fading medium was used with QDs in 3T3 cell 
photobleaching experiments [181]. This observation could be the result of having an 
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additional thiol group to replace the dynamic thiol bonds at the nanoparticle surface, 
preserving photostability and increasing photoluminescence. 
From the results of this, and previous researchers' studies, oxygen appears to be 
the dominant ambient factor in decreasing photoluminescence. The reduction in signal 
measured from p-micelles maintained in dark conditions (except for during emission 
recording at discrete time-points) was significantly less than that observed under 
continuous illumination (Fig. 2(c)). This finding suggests that continuous exposure to 
light degrades photoluminescence intensity in the presence of oxygen. 
We performed fluorescence confocal microscopy to evaluate the p-micelle QDs 
and cAmp QDs under practical biological imaging conditions (Fig. 3). The results of this 
experiment were in agreement with the data from the spectroscopy experiments, with the 
cAmp QDs retaining their emission intensity, and the p-micelle QD intensity reduced to 
50% of the original level, over a 2 min. continuous photobleaching session. Evaluating 
the performance of the QD coating under confocal microscopy is an important step in 
supporting the translation of our spectroscopic results to situations encountered in 
practical biological imaging. 
3.7 Conclusion 
We used a combination of spectroscopy and imaging techniques to determine the 
effects of light, oxygen and coating integrity on QD photoluminescence. We evaluated 
amphiphilic-polymer based coatings that were very similar in chemical composition but 
quite different in their association with the QD surface, due to the packing and size of 
their hydrophobic regions. This surface association is of considerable importance in 
determining the susceptibility of the QD to oxidation and related loss of 
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photoluminescence. The coating with the most rigid structure, associating permanently 
with the QD surface, exhibited the greatest degree of photostability. Crosslinks in the 
coating structure combined with a large hydrophobic region provided the greatest degree 
of hindrance to oxygen diffusion. In contrast, the dynamic micelle structure with its 
significantly smaller hydrophobic region allowed oxygen to diffuse to the QD surface 
relatively easily, resulting in a substantial reduction in photostability. This study 
illustrates the importance of passivating QDs with ligands that are both impermeable to 
oxygen, and strongly associated with the QD surface in order to preserve photostability 
for biological imaging applications. 
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CHAPTER 4: TARGETING OF EGFR USING ANTIBODIES AND 
PEPTIDES IN VITRO, EX VIVO AND IN VIVO 
4.1 Abstract 
Epidermal growth factor receptor (EGFR) is thought to be a promising target for 
optical contrast agents because its expression is upregulated in a variety of cancers. Both 
antibody and peptide-based optical contrast agents have been developed against EGFR 
expressing cells but have not been systematically tested in vitro and in vivo. We sought 
to compare the labeling of an EGFR-specific antibody (clone 108), mouse epidermal 
growth factor (mEGF), and human epidermal growth factor (hEGF) each coupled to an 
Alexa Fluor© 647 dye in EGFR-positive and EGFR-negative cells and tumors using 
confocal microscopy. Topical delivery in cells and tissues was compared to labeling via 
an intravenous delivery route. To quantitatively evaluate differences in labeling, the 
measured mean fluorescence intensity was normalized for differences in the contrast 
agent dye to protein ratio. Labeling with anti-EGFR and hEGF conjugates was 
consistently more intense than labeling with mEGF, both in vitro and in vivo. The 
cellular localization of labeling varied between conditions, with topical labeling at 4 °C 
yielding an extracellular signal and intravenous labeling yielding both intracellular and 
extracellular signals. In vitro studies of receptor-mediated internalization were used to 
confirm that all contrast agents tested can be internalized at 37 °C. This study 
demonstrates that with use of appropriate methodology, it is possible to compare in vitro 
and in vivo targeting of optical contrast agents. 
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4.2 Introduction 
Optical imaging approaches utilizing molecular specific contrast agents have the 
potential to allow events accompanying neoplastic transformation and progression to be 
visualized. The development of contrast agents for optical molecular imaging requires 
that a probe molecule specific to a recognized biomarker of neoplastic transformation be 
tethered to an optically active reporter. Such contrast agents generally target the 
molecular features of cancer by exploiting high affinity proteins [182], which can range 
in size from 5 kDa (peptides) to 150 kDa (antibodies). 
EGFR is a promising biomarker for non-invasive optical detection of cancer. 
EGFR is a 170-kD transmembrane receptor tyrosine kinase that is over-expressed in 
human malignancies including breast cancer, glioma, and lung cancer [1-3]. The over-
expression of EGFR has been correlated with many processes related to cancer, including 
uncontrolled cell proliferation, autocrine stimulation of tumor growth by tumors 
producing their own growth factors, and prevention of cellular apoptosis [183]. 
Antibodies [184-186], Fab fragments [187, 188], and peptides [186, 189, 190] have all 
been shown to target EGFR with high specificity. 
In designing optical contrast agents to target EGFR, it is important to understand 
targeting specificity and delivery issues encountered in vivo. Highly specific anti-EGFR 
antibodies have shown promise as optical contrast agents in pre-clinical animal models; 
however in vivo use is often limited by their large size and non-specific uptake by the 
liver and reticuloendothelial system [191]. EGF peptides have been show to specifically 
label EGFR expressing tumors when delivered intravenously [192], but are limited by 
short plasma half-life, often reducing accumulation in the tumor [186]. Additionally, 
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EGF peptides have been shown to activate the EGFR pathway, whereas antibodies to 
EGFR do not, illustrating different biological effects on cells [192]. EGF peptides have 
not been systematically characterized and compared to antibodies for in vivo applications 
Although different proteins exist to target EGFR, they have not been 
systematically evaluated. In this study we aim to evaluate different proteins conjugated 
to Alexa 647 dye for their abilities to target EGFR in EGFR-positive cells and tissues 
through topical and intravenous delivery. Antibodies (large: 150 kDa) and peptides 
(small: 5 kDa) to EGFR were chosen because they represent the size extremes of 
available targeted delivery proteins. Two peptides were chosen, human epidermal 
growth factor (hEGF) and mouse epidermal growth factor (mEGF), to investigate 
whether the human form of the peptide would have a higher affinity than mouse peptide 
for the human cell lines used in this study. Each contrast agent was evaluated in EGFR-
positive cells, in topically-labeled EGFR-positive tumor slices, and via intravenous 
delivery to EGFR-positive tumors in an in vivo xenograft model. Confocal fluorescence 
images were acquired from each experimental model, with quantitative comparisons 
made after accounting for differences in dye loading capacity, by normalizing the mean 
fluorescence intensities to the dye:protein ratio. 
Anti-EGFR and hEGF conjugates consistently demonstrated higher normalized 
mean fluorescence intensities than mEGF conjugates, in EGFR-positive cells and tissues, 
regardless of delivery method. When topically labeled with each contrast agent at 4 °C, 
EGFR-positive cells and tumor slices exhibited fluorescence intensity confined to cell 
membranes. In contrast, when each agent was delivered intravenously to EGFR-positive 
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tumors, excised tissue primarily exhibited intracellular fluorescence intensity, as was also 
seen in EGFR-positive cells labeled at 37 °C. 
We conclude that when targeting EGFR with protein-based contrast agents, the 
degree of labeling intensity and localization can depend on the properties of the targeting 
protein and specific labeling conditions. These factors should be taken into consideration 
in future development of contrast agents to target EGFR in vivo. 
4.3 Materials and Methods 
4.3.1 Cell culture 
1483 cells, derived from a patient with head and neck squamous cell carcinoma of 
the retromolar trigone and known to over-express EGFR [193], were provided by Dr. 
Reuben Lotan (M. D. Anderson Cancer Center, Houston, TX). MDA-MB-435S cells 
(American type culture collection, Manassas, VA), derived from ductal adenocarcinoma 
of the breast, express no EGFR [194] and were used as a negative control. 1483 cells 
were grown in Dulbecco Modified Eagle Medium (Invitrogen, Carlsbad, CA). MDA-
MB-435S cells were cultured in Minimal Essential Media supplemented with sodium 
pyruvate, L-glutamine, vitamins, and non-essential amino acids (Invitrogen). All cell 
culture medium was enhanced with 10% fetal bovine serum (Hyclone, Logan, UT). 
4.3.2 Contrast agent synthesis and characterization 
Recombinant human epidermal growth factor (hEGF; Millipore, Billerica, MA), 
recombinant mouse epidermal growth factor (mEGF; Millipore), mouse anti-human 
EGFR antibody (clone 108, custom synthesized by Baylor College of Medicine, Houston, 
TX), and mouse anti-human IgGl (Invitrogen) were individually reacted with 
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AlexaFluor® 647 carboxylic acid succinimidyl ester (Invitrogen, Carlsbad, CA) using 
commercially available labeling kits (Invitrogen). The protein-dye conjugates were 
purified using Zeba columns (Pierce, Rockford, IL) and then dialyzed against phosphate 
buffered saline (PBS, Sigma-Aldrich, St. Louis, MO) for 4 days at 4 °C using tubing with 
a 3500 MW cut-off (Pierce). The conjugates were monitored for dye removal by 
measuring the absorbance of the dye peak during regular intervals. The purified 
conjugates were suspended in PBS at a concentration of 1.0 to 10.0 uM. The spectral 
absorption characteristics of each conjugate were measured using a Cary 50 UV-Vis 
Spectrophotometer (Varian Inc., Palo Alto, CA). The molar dye-to-protein (dye:protein) 
ratio was estimated using Beer's Law and the measured dye and protein absorbance 
peaks. The measurement of dye:protein was performed for each conjugation of anti-
EGFR (n=8), hEGF (n=6), mEGF (n=6) and IgG (n=4) to Alexa 647. 
4.3.3 Contrast agent validation in vitro 
To assess the specificity of the different contrast agents to target EGFR, 
subconfluent monolayers of 1483 and 435S cells (5 x 104 cells/cm2) were treated with 
0.1 uM anti-EGFR-Alexa 647, 0.1 uM IgG-Alexa 647, 9 uM mEGF-Alexa 647, or 4 uM 
hEGF-Alexa 647. The concentration of both peptide-dye conjugates was adjusted to 
yield the same optical density at 280 nm to ensure same amount of protein available for 
targeting. Briefly, the cell monolayers were blocked with 10% bovine serum albumin 
(Sigma-Aldrich) for 20 minutes, incubated with protein-dye conjugate for 1 hour, and 
then washed 3 times in PBS. All labeling was performed at 4°C. These experiments 
were repeated 4 times in duplicate. The degree of labeling was quantitatively assessed 
from confocal fluorescence images as described below. 
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To track the localization and internalization of EGFR labeling as a function of 
time, 1483 and 435S cells were plated at an appropriate density to allow log-linear 
growth for 48 hours. This experiment was repeated four times. Cells were labeled with 
0.1 uM antiEGFR-alexa647, 0.1 uM IgG-Alexa 647, 9 uM mEGF-Alexa 647 or 4 uM 
hEGF-Alexa 647 and diluted in phenol-free media supplemented with antibiotics 
(Invitrogen). Cells were incubated at 37° C for 48 hours. After 48 hours, the dye 
localization was determined using confocal microscopy (described below). 
4.3.4 Tumor xenograft model 
Subcutaneous tumors were generated in mice as a model for ex vivo and in vivo 
EGFR targeting. 1483 or 435S cells (2 x 106 viable cells in 100 ul PBS) were injected 
into the right mammary fat pad of female, Nu/Nu-Foxnlnu mice (Charles River 
Laboratories, Wilmington, MA). The mice were housed under sterile conditions at Rice 
University and all experiments were performed in accordance with the guidelines of the 
Institutional Animal Care and Use Committee. When the tumors reached 4-5 mm in 
diameter, the tumors were excised for ex vivo labeling or labeled with EGFR-specific 
contrast agents via intravenous injection as described below. 
4.3.5 Evaluation of contrast agent labeling ex vivo 
To evaluate EGFR targeting in fresh tumor slices, 4 tumors of 4-5 mm diameter 
were excised and sliced into 200 urn thick transverse slices using a Krumdieck tissue 
slicer (Alabama Research & Development, Munford, AL). Four slices from each tumor 
were analyzed per contrast agent (anti-EGFR-Alexa 647, IgG-Alexa 647, mEGF-Alexa 
647, and hEGF-Alexa 647). The tissue slices were blocked with 10% bovine serum 
albumin in PBS for 20 minutes and then labeled with 0.1 uM antiEGFR-Alexa 647, 0.1 
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uM IgG-Alexa 647, 9 uM mEGF-Alexa 647 or 4 uM hEGF-Alexa 647for 1 hour at 4 °C. 
The EGFR-targeting solutions were supplemented with 10% DMSO to enhance tissue 
penetration [184]. The tissue slices were subsequently washed 3 times with PBS, 
counter-stained with 0.05 % acriflavine-hydrochloride (Sigma-Aldrich), and imaged 
using confocal microscopy. The degree of labeling was quantitatively assessed from 
confocal fluorescence images as described in detail later. 
4.3.6 Evaluation of contrast agent labeling in vivo 
To evaluate EGFR targeting in vivo, 0.1 to 1 nmol of anti-EGFR-Alexa 647, IgG-
Alexa 647, mEGF-Alexa 647, or hEGF-Alexa 647 conjugate, was injected intravenously 
via the tail-vein of tumor-bearing mice. For 1483 tumors, each targeting protein (anti-
EGFR, mEGF, hEGF) conjugated to Alexa 647, was injected separately into 4 mice. 
IgG-Alexa 647 and dye only controls were injected into 2 and 1 mice respectively. The 
same number of mice and controls were used for the 435S tumors. Forty-eight hours 
after injection, the tumors were resected and sliced into 200 urn thick transverse slices 
using a Krumdieck tissue sheer. This time point was chosen to provide sufficient 
contrast agent delivery and the clearance of non-specific signal from circulation [182]. 
Four slices from each tumor were evaluated. Immediately prior to imaging, the tissue 
slices were counter-stained with acriflavine-HCL for 30 seconds. The fresh tissue slices 
were evaluated for EGFR and acriflavine-HCL labeling using confocal microscopy. In 
addition, unlabeled control tumors (n=2 for 1483, n=2 for 435S) were resected and fixed 
in 10% formalin for EGFR immunohistochemistry. Unlabeled tumors were used for 
EGFR IHC to prevent any interference from contrast agents administered via intravenous 
injection. 
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4.3.7 Confocal imaging and analysis 
Confocal fluorescence images were obtained using a Carl Zeiss LSM 510 
confocal microscope (Thornwood, New York) equipped with 488 nm (30mW) and 633 
nm (5 mW) lasers. Images were collected using PMT detectors and Zeiss LSM 5 image 
examiner software. For AlexaFluor 647 detection, samples were excited at 633 nm 
(100% laser power) and the fluorescence emission was collected using a 650-710 nm 
band-pass filter. For acriflavine detection, samples were excited at 488 nm (50% laser 
power) using a 505-550 nm band-pass filter. Images were acquired using 40x (NA = 
1.3) or 63x (NA= 1.4) oil objectives with a pinhole of 1.0 Airy units. The gain was 
independently adjusted for each contrast agent to compensate for differences in dye 
loading. Final images were normalized for differences in gain before analysis. 
To quantitatively compare EGFR labeling using different contrast agents targeting 
EGFR in cells and tissues, representative confocal fluorescence images were processed in 
Image J (National Institutes of Health, Bethesda, MD). Four sets of representative 
regions of interest (ROI) from 2 experiments were evaluated for each experimental 
condition. Regions of non-necrotic squamous cells were identified by the presence of 
strong acriflavine signal. The total fluorescence intensity of each ROI was determined. 
The measured total intensity within each ROI was then normalized relative to the number 
of cells per ROI, the confocal detector gain, and the dye:protein ratio of the appropriate 
contrast agent. The intensities of four experimental conditions (anti-EGFR, IgG, mEGF, 
and hEGF coupled to Alexa 647) were compared pair-wise using a Student's t-test, with a 
p-value of <0.05 considered statistically significant. 
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4.4 Results 
4.4.1 Contrast agent characterization 
The dyerprotein ratio was independently measured for each round of contrast 
agent synthesis for quality control and comparison purposes. Table 1 shows the mean 
dye:protein ratio measured over all synthesis batches and the number of batches 
examined (n). The degree of dye loading was highest for the antibodies. Dye loading of 
mouse and human EGF peptides, which have 1 and 3 conjugation sites respectively [189, 
195], was generally limited to less than 1 dye molecule per peptide. 
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Table 4-1: Dye loading of EGFR-targeted contrast agents as measured by the dye to 
targeting protein molar ratio (dye:protein). N represents the number of synthesis batches 
measured. 
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4.4.2 Anti-EGFR labeling 
Monolayers of cells and tumors were treated with anti-EGFR targeted Alexa 647 
contrast agents and evaluated for the degree of EGFR labeling. Fluorescence images of 
1483 and 435S cells and tumors treated with anti-EGFR targeted Alexa 647 are shown in 
Figure 1 along with EGFR immunohistochemistry. Positive labeling characterized by a 
distinctive honeycomb pattern of fluorescence is seen in for the 1483 cells and tumors 
labeled with anti-EGFR targeted Alexa 647 (Fig. la, lb, and lc). Little to no 
fluorescence is seen in EGFR-negative 435S cells and tumors (Fig. le, If, and lg) or in 
IgG-Alexa 647 controls (data not shown). EGFR immunohistochemistry confirmed 
positive EGFR labeling was limited to 1483 tumors (Fig. Id and lh). 
The pattern of labeling differed between the topical and intravenous delivery 
techniques. Topical labeling, performed at 4 °C, resulted in labeling along the cell 
membrane of EGFR-positive cells and tumors. Intravenous labeling led to partial 
internalization of the contrast agent, yielding cells with labeling along both the cell 
membrane and cytoplasm. Topical labeling was more uniform than in vivo labeling of 
1483 tumors as evidenced by the distribution of fluorescence signal in the field of view of 
the confocal images. 
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EGFR IHC 
Figure 4-1: Representative confocal fluorescence images of EGFR targeting with anti-
EGFR- Alexa 647 in EGFR-positive 1483 cells and tumors (top panel) and EGFR-
negative 435S cells (bottom panel). The panels show representative labeling of cells in 
vitro (a, e), tumors labeled topically ex vivo (b, f) and intravenously in vivo (c,g). Scale 
bar represents 50 um in fluorescence images and 100 urn in IHC images. The observed 
pattern of labeling is comparable to EGFR immunohistochemistry of 1483 (d) and 435 
(h) tumors. 
4.4.3 Peptide labeling 
Monolayers of cells and tumors were treated with either mEGF- or hEGF-targeted 
Alexa 647 and evaluated for the degree of EGFR labeling. Confocal fluorescence images 
of mEGF- and hEGF- targeted Alexa 647 in 1483 and 435S cells and tumors 
administered in vitro, ex vivo and in vivo are shown in Figure 2. Positive labeling, 
characterized by a distinctive honeycomb pattern was observed in 1483 cells and tumors 
topically labeled with either mEGF- (Fig.la and lb) or hEGF-targeted (Fig.Id and le) 
contrast agents. 1483 cells and tumors topically labeled in vitro and ex vivo with hEGF 
conjugate had significantly higher fluorescence intensities when qualitatively compared 
In vitro ex vivo in vivo 
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to those labeled with mEGF conjugate. EGFR-negative 435S cells and tumors topically 
labeled with hEGF or mEGF conjugates showed negligible levels of fluorescence (data 
not shown). When the peptides were delivered to 1483 tumors via intravenous delivery, 
hEGF-Alexa 647 resulted in a stronger fluorescence signal than mEGF-Alexa 647. In 
both cases, positive labeling with intravenous administration of both peptides was limited 
to the squamous regions of 1483 cell tumors. Peptide conjugates administered 
intravenously to the EGFR-negative 435S tumors resulted in negligible fluorescence. 
The pattern of labeling with hEGF and mEGF conjugates differed between topical 
and intravenous administration. Topical delivery of hEGF and mEGF conjugates at 4 °C, 
resulted in labeling along the cell membrane of EGFR-positive cells and tumors. Topical 
delivery of both peptide conjugates resulted in a more uniform distribution of 
fluorescence signal than in vivo delivery. Little to no signal was seen in the EGFR-
negative cells and tumors (data not shown). When delivered intravenously, the 
fluorescence signal was primarily intracellular with both peptide conjugates. 
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In vitro ex vivo in vivo 
Figure 4-2: Representative confocal fluorescence images of EGFR targeting in 1483 cells 
and tumors using mouse and human EGF targeted Alexa 647. The panels show 
representative labeling of cells in vitro (a, d), tumors labeled topically ex vivo (b, e) and 
intravenously in vivo (c, f). Scale bar represents 50 um. 
4.4.4 Contrast agent uptake of live cells in vitro 
To better understand the internalization of contrast agents targeting EGFR in vivo, 
live cells were topically labeled for 48 hours at 37 °C. Figure 3 shows the pattern of 
fluorescence labeling after 48 hours incubation of anti-EGFR-, mEGF- and hEGF-Alexa 
647 conjugates (false colored-red) with 1483 and 435S cells. The 48 hour experiments in 
1483 cells show that anti-EGFR antibody retains membrane bound signal, while some 
signal is internalized (Fig. 3 panel A). With both peptides, the signal is primarily 
intracellular. The same studies were performed with 435S cells and showed little 
(peptides) to no (anti-EGFR antibody) intracellular signal. (Fig.3 panel B). Localization 
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with respect to acriflavin signal (false-colored green) shows that the internalized 




Figure 4-3: False-colored fluorescence confocal images 
showing the internalization of antibody and peptides 
conjugated to Alexa 647 and incubated with 1483 (Panel A) 
and 435 (Panel B) for 48 hrs at 37 °C. A fluorescence 
nuclear counter-stain (false-colored green) shows that all 
internalized signal due to antibody and peptide targeing 
(false-colored red) remains cytoplasmic. The EGFR-
negative cell line shows little fluorescence signal due to 
targeting. Scale bar represents 20 um. 
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4.4,5 Quantitation of fluorescence labeling 
Normalization of the mean fluorescence intensity measured from representative 
images to the dye:protein ratio allows a quantitative comparison of labeling achieved 
with different contrast agents targeting EGFR. Mean fluorescence intensities of each 
protein-dye conjugate targeted to 1483 cells in vitro, ex vivo, and in vivo, normalized to 
the protein-dye ratio, are shown in Figure 4. Anti-EGFR conjugates labeled EGFR-
positive cells in vitro with a normalized mean fluorescence intensity approximately 2 
times that of hEGF conjugates and 4 times that of mEGF conjugates. The highest 
intensity labeling per cell was observed in topically labeled ex vivo tissue, where anti-
EGFR conjugates had a normalized mean fluorescence intensity approximately 2 and 4 
times that of hEGF and mEGF conjugates. The lowest intensity labeling per cell was 
seen with in vivo delivery of the contrast agents. The normalized mean fluorescence 
intensity of hEGF and anti-EGFR in vivo were 3.6 and 2.5 times that of mEGF. Little to 
no labeling was observed with IgG-Alexa 647. All measured fluorescence intensities 
were statistically significant (p < 0.05) when compared pair-wise with the exception of 



























in vitro ex vivo in vivo 
Figure 4-4: Comparison of the measured mean fluorescence intensity of EGFR labeling 
per cell in vitro, ex vivo and in vivo, normalized to dye:protein ratio for each protein 
tested. Compared pair-wise in each experimental labeling condition (in vitro, ex vivo, 
and in vivo), the performance differences between each conjugate were statistically 
significant (p < 0.05) with the exception of anti-EGFR and hEGF in vivo. 
4.5 Discussion 
Molecular-specific contrast agents targeted to EGFR are of potential use for 
diagnostic imaging. The success of a contrast agent relies heavily on recognition events 
between the targeting moiety and the receptor. It is therefore critical to choose the best 
targeting moiety. We characterized an antibody and two peptides used to target EGFR to 
better understand the influence of targeting protein choice on contrast agent performance. 
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In all scenarios, anti-EGFR targeted Alexa 647 labeled EGFR-positive cells and 
tissues with a distinctive, honeycomb pattern of fluorescence consistent with EGFR IHC. 
Topical labeling experiments performed at 4 °C demonstrate that this contrast agent 
specifically targets the extracellular membrane of EGFR-positive cells and tissues. Since 
EGFR is a transmembrane protein that undergoes very little endocytosis at 4 °C, 
fluorescence is seen primarily at the cell membrane. The honeycomb pattern of EGFR 
labeling with antibody becomes intracellular when administered in vivo due to receptor 
internalization at 37 °C [196]. This pattern of labeling was consistent with published 
results of antibody-based targeting [182]. When topically delivered to EGFR-positive 
cells and tissues at 4 °C, both peptides labeled EGFR-positive cells and tissues with a 
membrane fluorescence pattern similar to anti-EGFR targeted dye. When delivered 
intravenously, peptide targeted dyes did not show a distinctive honeycomb pattern but 
fluorescence was intracellular. 
As experiments move in vivo, it is hard to interpret results due to the multitude of 
variables involved. It was therefore important to recapitulate in vivo results through in 
vitro experiments. In order to do this, cells were incubated with each protein-dye for 48 
hours at 37 °C. This provided a simplistic approach to remove any possible issues 
complicating in vivo delivery such as glomerulous filtration, blood clearance rates, and 
enzymatic degradation of the contrast agents. Such studies also help elucidate the 
difference seen between mEGF and hEGF conjugates labeling EGFR in vivo and 
determine if these labeling differences are due to a biological phenomenon occurring 
exclusively in vivo. After 48 hours, the majority of fluorescence signal with both peptides 
was intracellular, as visualized with respect to counter-stained nuclei, whereas anti-EGFR 
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signal was both intracellular and along the membrane. The intracellular labeling 
appeared punctate suggesting lysosomal localization similar to patterns of EGF peptide 
and anti-EGFR antibody uptake reported elsewhere that were attributed to lysosomal and 
endosomal sorting of the internalized receptors [196-198]. Lysosomal degradation is the 
ultimate fate of EGF ligand/ EGF receptor complexes, therefore the intracellular 
punctuate labeling pattern is consistent with the nature of these complexes [198]. The 
uptake of mEGF conjugate in cells for 48 hours was less than that of either hEGF or anti-
EGFR conjugates, but was still substantial. 
In order to provide a meaningful quantification of the targeting studies performed, 
we removed any contribution that the dye loading would have in analysis. Differences in 
dye loading could cause the differences in targeting to be greatly exaggerated and were 
compensated for by normalizing the measured mean fluorescence intensity by the 
dye:protein ratio. The antibodies tested, anti-EGFR and IgG, both showed similar levels 
of dye loading that were consistent with literature [199]. As for peptide conjugation to 
dye, hEGF had a higher dye:protein ratio than mEGF (0.96 versus 0.67). The mEGF 
dye:protein ratio is similar to measurements in literature where mEGF was conjugated to 
Cy5.5 [190]. Since hEGF has two amine groups in addition to the terminal amine group 
shared by hEGF and mEGF [189], it theoretically could load 3 times the dye as compared 
to mEGF. However, based on measurements, only a 1.5 times increase in dye:protein 
ratio over mEGF dye:protein ratio is seen with hEGF due to the conjugation efficiency of 
the reaction. 
Once normalized for dye:protein ratio, the labeling differences became less 
pronounced but in most cases still statistically significant. Both anti-EGFR and hEGF 
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repeatedly performed better than mEGF. When topically labeled, anti-EGFR resulted in 
mean fluorescence intensity 2 times stronger than hEGF and 4 times stronger than mEGF 
both in EGFR-positive cells and tissues. Mouse peptide delivered intravenously to 
EGFR-positive tumors had a mean fluorescence intensity that was approximately one 
third that of hEGF and antiEGFR. When delivered intravenously, no significant 
difference in the mean fluorescence intensity of antibody and hEGF peptide was 
observed. We speculate that hEGF activation of EGFR endocytosis and recycling in vivo 
may facilitate cell loading, thereby minimizing the differences in mean fluorescence 
intensity seen between hEGF and anti-EGFR. The performance of mEGF targeted 
delivery to human cell lines and tumors relative to hEGF suggests that hEGF peptides 
have a higher affinity for human cells. Differences in the mean labeling intensity 
observed between topically and intravenously delivered contrast agents is likely due to 
differences in delivery and contrast agent availability. 
This study as demonstrated that with the use of the appropriate methodology, it is 
possible to compare the in vitro and in vivo targeting capabilities of optical contrast 
agents. We characterized the performance of two peptides and one antibody to EGFR in 
cells and tissue using two delivery methods: topical and intravenous. In vitro cell 
labeling studies provided a simple first step to compare contrast agent targeting. The 
large transition from cells studies to in vivo delivery of contrast agents was bridged by ex 
vivo studies. Topical labeling of ex vivo tumor slices provided an understanding of how 
tissue labeling compared with cell labeling with regards to EGFR targeting. The proteins 
used to target EGFR in this study varied in their targeting capabilities and dye:protein 
ratio. Overall, anti-EGFR and hEGF conjugates had better protein targeting capabilities 
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than mEGF conjugates. Although anti-EGFR and hEGF had similar targeting capabilities 
in vivo, anti-EGFR carried 3 times the moles of dye per mole of protein, which 
potentially translates into 3 times the fluorescence signal per protein reaching EGFR. 
Anti-EGFR, due to the combination of targeting capabilities and high dye:protein ratio, is 
the best candidate for in vivo use based on the parameters investigated in this study. 
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CHAPTER 5: SUMMARY AND RESULTS 
5.1 Summary of results 
This dissertation provides a methodology for the development of optical contrast 
agents targeting epidermal growth factor receptor for in vivo detection. Epidermal growth 
factor receptor was chosen as a target because of its correlation with cancer severity. The 
optical components of the contrast agents developed were either an Alexa Fluor 647 or 
quantum dots chosen for their emission wavelength. EGF peptide ligands and an anti-
EGFR antibody were investigated as the targeting moieties for contrast agents. Each 
contrast agent was tested and evaluated in vitro, ex vivo, and in vivo for its ability to 
specifically label epidermal growth factor receptors. The work presented here could aid 
in designing an optical probe for epithelial cancer detection and treatment. 
In the third chapter of this dissertation, quantum dot photostability was evaluated 
as a comparison of different passivation strategies. In order for quantum dots to be 
applied to biological imaging, they must remain luminescent and be soluble in aqueous 
solutions. The importance of the passivating ligand's structure was demonstrated by 
comparing strategies which varied in level of polymer chain interactions. The ability of a 
ligand to provide the highest level of passivation was shown to be directly related to the 
amount of association between passivating ligands. Cross-linked amphiphilic polymers 
provided the best protection of quantum dots as compared to micelle-encapsulation or 
non-crosslinked amphiphilic polymers, which was reflected in the retention of a high 
level of luminescence when subject to continuous illumination. 
Chapter four investigated the choice of protein to target EGFR through the 
following delivery routes: in vitro; ex vivo; and in vivo. Each protein was conjugated to 
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Alexa Fluor 647. The specificity of each protein-dye was shown in vitro through cell 
labeling and competition assays. With each protein, the pattern of labeling of EGFR on 
the cell membrane was distinguishable for in vitro cell and ex vivo tissue labeling. Major 
differences in the pattern arose when each protein-dye was tested in vivo, where both 
anti-EGFR antibody and hEGF performed better than mEGF. The main difference that 
arose between the antibody and the human peptide was the higher dye to protein ratio of 
the antibody, which resulted in a higher fluorescence signal per cell receptor. Once this 
was taken into account, differences amoung all the proteins tested decreased and 
differences between antibody and human peptide were statistically insignificant. 
5.2 Future directions 
While the research presented here provides effective optical strategies to target 
the epidermal growth factor in vivo, further research must be performed to fully evaluate 
and understand the delivery issues involved in labeling tumors in vivo. An ideal probe 
would allow optimal delivery, efficient tissue perfusion, good targeting to specific sites 
within the tumor, and timely, complete clearance of any non-specific probe. 
Additionally, the probe should be as nonimmunogenic as possible, thereby reducing the 
host immune response. Such probes have potential applications in identifying tumors and 
micrometastases throughout the body. 
In order to optimize the amount of protein-dye delivered to tumors, futher 
biodistribution studies should be performed. These studies would aid in understanding 
the differences in blood residence and clearance times of each protein-dye conjugate 
tested. At several time points after intravenous injection of protein-dye contrast agents, 
blood can be drawn and urine collected to understand both residence time in circulation 
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and glomerulous filtration. This might aid in understanding and the differences in in vivo 
labeling seen with peptides and antibody. Any such data would aid in the development of 
protein directed optical probes for optimized delivery to tumors. 
This dissertation has demonstrated that lower molecular weight proteins such as 
peptides and medium molecular weight antibodies can be delivered to tumors, perfuse 
and label EGFR specifically. A more direct comparison of the ability of each protein-dye 
to diffuse and penetrate through the tumor from vascularization could be performed. 
Protein-dye conjugates could be delivered via intravenous injection as before and 
topically labeled after excision and slicing with a fluorescence dye attached to an 
endothelial marker such as von willebrand factor. The endothelial marker would 
delineate any vasculature and the distance the protein-dye traveled from the vasculature 
could be measure on a confocal microscope. 
It would be useful to determine the cutoff molecular weight for successful 
intravenous delivery to a solid, subcutaneous tumor. This knowledge will create a more 
complete picture of in vivo delivery issues. Size of probe-protein could be systematically 
increased (while trying to keep charge as constant as possible) by next deliverying a QD-
peptide and then a QD-protein. Counter-staining the excised tumor slices again with an 
endothelial marker as above would allow delivery to be assessed. 
The desired end application of the contrast agents described in this dissertation 
would be an in vivo probe identify tumors and metastases, or to guide in tumor resection 
by delineating margins. In all cases, intravenous administration of the contrast agent 
would be followed by a waiting period which would allow any non-specific probe to be 
cleared from circulation which would create a background signal possibly obscuring true 
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signal. It is essential for the non-specific signal to clear so that true signal, due to the 
over-expression of EGFR, could be visualized in vivo. The time point of 48 hrs was used 
for in vivo studies in this dissertation since literature shows this is an optimal time point 
to maximize the signal to background [182]. A future study should include a comparison 
of time points for peptide versus antibody with both dye and QDs to establish the time to 
achieve the best signal to background. 
A disadvantage of using an EGFR targeted probe for in vivo applications is the 
high EGFR expression level in the liver (106) [200] which is the same order of magnitude 
of some tumors. Ideally, the probe would not cause harm and would still have a high 
concentration available for tumor targeting after passing through the liver. Studies 
should be performed to compare loss in the liver and see if it differs among the targeting 
proteins chosen. Loss in the liver have been reduced by as much as 45% through 
antibody PEGylation without affecting tumor uptake [201] 
An in vivo assay for cytotoxicity should be performed on all protein-dyes. Before 
performing in vivo cytotoxicity tests, it would be beneficial to establish the cytotoxicity in 
vitro. The effects of dye-proteins on cell growth, morphology and viability should be 
established. In the 48 hour live cell labeling studies performed in chapter 4, cell 
morphology appeared healthy after incubation with protein-dyes. A more quantitative 
assessment of cytotoxicity must be performed first in vitro and then in vivo. To assess 
cell viability after administration of each protein-dye in vitro, an MTT assay should be 
performed as well as population double studies. The MTT assay would provide a 
measure of cell viability after exposure to each protein-dye for certain time periods. It 
has been shown with Alexa Fluor 660, that cells were relatively unaffected for time 
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periods up to 2 days [184]. Finally, to establish the effect on viability, each dye-protein 
must be applied to cells in vitro, cultured, and population doubling rate compared to cells 
without dye-protein. These tests should then be translated in an in vivo mouse model. 
The long-term goal of optical probe design would be to aid in the identification of 
early mestasis and small primary tumors. The xenograft subcutaneous mouse model was 
was used as a simple proof of principle comparison of the in vivo performance of targeted 
dyes. It is believed that orthotopic implantation or genetically engineered transgenic 
animals are more realistic models [202]. Also, trying to identify a millimiter sized tumor 
superficially placed is much easier than identifying micrometasis deep within tissues and 
organs. In order to further test the practicality of using such optical probes, a mouse 
model involving metatasis should be used. 
Clearly, in vivo applications have many challenges that need to be addressed to 
successfully design a protein-dye or protein-QD probe. However, the foundations 
presented in this dissertation provide a promising starting point for issues related to the in 
vivo targeting of EGFR with protein-dye and protein-QD probes. Futher investigations 
and experiments might result in identifying the best fluorophore-protein combination for 
maximium tumor localization. These probes could someday aid in the detection of 
tumors or micrometasis in vivo resulting in increased patient survival. 
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